DISCLAIMER
This web site contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the company's control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

Date Title   09/03/10 Celgene Officially Notified of ANDA Filing for REVLIMID(R) SUMMIT, N.J., Sep 03, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). The application requests authorization to manufacture and market generic versions of REVLIMID(R) (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States. Celgene intends to vigorous...  08/26/10 Celgene Corporation Announces Appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer SUMMIT, N.J., Aug 26, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) todayannounced the appointment of Jacqualyn A. Fouse as Senior Vice President and Chief Financial Officer, effective September 27, 2010. Ms. Fouse will be responsible for all finance operations at Celgene and will report to Robert J. Hugin, Chief Executive Officer of Celgene Corporation. Fouse succeeds David W. Gryska, who served as Senior Vice President and Chief Finan...  08/25/10 Celgene Expects to Receive a Paragraph IV Notification of an ANDA Filing for REVLIMID(R) SUMMIT, N.J., Aug 25, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer. Celgene intend...  08/20/10 REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan BOUDRY, Switzerland, Aug 20, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients...  08/04/10 Celgene/Abraxis Receive Verbal Confirmation of Early Termination of Hart-Scott-Rodino (HSR) 30-Day Waiting Period SUMMIT, N.J., Aug 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regard to Celgene's pending acquisition of Abraxis Bioscience, Inc. (NASDAQ: ABII). Celgene anticipates that the transaction will be completed in the th...  07/29/10 Celgene Reports Record Second Quarter 2010 Operating and Financial Results Record Second Quarter Results Driven By Market Share Gains Across Major Markets REVLIMID(R) Second Quarter Global Net Product Sales Increased 48% Y/Y VIDAZA(R) Second Quarter Global Net Product Sales Increased 43% Y/Y Non-GAAP Second Quarter Diluted Earnings Per Share Increased 50% Y/Y SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2010 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GA...  07/19/10 Celgene Corporation to Announce Second Quarter 2010 Results on July 29, 2010 SUMMIT, N.J., Jul 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 29, 2010 at 9 a.m. ET to discuss the company's second quarter 2010 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated g...  06/30/10 Celgene to Acquire Abraxis BioScience Inc. ABRAXANE(R) Approved for Second-Line Use in Metastatic Breast Cancer, Establishes Celgene in Solid Tumors Complementing Its Leadership Position in Blood Cancers Recent Clinical Data Presented at ASCO and AACR for ABRAXANE in First-Line Non-small Cell Lung Cancer and First-Line Pancreatic Cancer Highlights Significant Growth Opportunities Celgene Reaffirms 2010 Non-GAAP Financial Outlook; Expects Acquisition to be Modestly Dilutive to Non-GAAP Earnings in...  06/24/10 Revlimid® Granted Approval for Treatment of Relapsed or Refractory Multiple Myeloma in Japan (June 24, 2010) – Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan. Multiple myeloma is the second m...  06/14/10 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J., Jun 14, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. On Thursday, June 17, 2010, Celgene will present at the Goldman Sachs 31st Annual Healthcare Conference at 10:00 a.m. PT. ...  06/12/10 Updated Results of Phase III Study Evaluating Continuous REVLIMID(R) Therapy in Newly Diagnosed Multiple Myeloma BOUDRY, Switzerland, Jun 12, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival (PFS), the primary endpoint of the study. The data were presented ...  06/07/10 Data from Study of Revlimid(R) in Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Presented at ASCO BOUDRY, Switzerland, Jun 07, 2010 (BUSINESS WIRE) --ABSTRACT #6508 Celgene International Sàrl (NASDAQ:CELG) today announced thatresearchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology. Results of the Phase II single-arm study reported that at a median follow-up of 23 months, the overall...  06/06/10 At ASCO, Oral Presentation from Intergroupe Francophone Du Myelome (IFM) of Phase III Study (IFM 2005 02) Evaluating Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the American Society of Clinical Oncology. Results of the study (IFM 2005 02) demonstrated that patients with multiple myeloma receiving continuous lenalidomide (REVLIMID) following a first-line autologo...  06/06/10 Oral Presentation at ASCO from Intergroup Phase III Study (CALGB 100104) Evaluates Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the annual meeting of the American Society of Clinical Oncology. Results of the Phase III, randomized, controlled, double-blind, multi-center clinical study of patient...  06/06/10 Randomized Phase III Study Comparing REVLIMID(R) Plus Melphalan and Prednisone (MPR) Compared to Autologous Stem Cell Transplant Presented at ASCO BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of lenalidomide plus low-dose dexamethasone (Rd) were presented at the Amer...  06/05/10 Data from Pomalidomide Study in Refractory Multiple Myeloma Patients Presented at ASCO BOUDRY, Switzerland, Jun 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced results of a Phase II study of pomalidomide and dexamethasone in multiple myeloma patients who have failed both lenalidomide and bortezomib. Data were presented by Dr. Martha Lacy of the Mayo Clinic during the American Society of Clinical Oncology annual meeting. Patients with multiple myeloma who have progressed after multiple therapies have li...  06/04/10 Evaluation of REVLIMID(R) in Patients with Either GCB or Non-GCB Diffuse Large B-Cell Lymphoma Presented at ASCO BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced researchersat the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma (DLBCL) either with a germinal center B-cell (GCB) or non-germinal center B-cell (non-GCB) phenotype. Investigators retrospectively analysed pooled patient data f...  06/04/10 Data from Combination of REVLIMID(R) and Rituxan(R) in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma Presented at ASCO BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology. Patients in the study had previously untreated indolent NHL with stage III or IV...  05/28/10 Celgene Corporation to Present at Three Upcoming Investor Conferences SUMMIT, N.J., May 28, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at three upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. On Thursday, June 3, 2010, Celgene will present at the Sanford C. Bernstein 26th Annual Strategic Decisions Conference 20...  05/27/10 Celgene Announces Dismissal of Suit against Barr Laboratories Following Withdrawal of Thalidomide ANDA SUMMIT, N.J., May 27, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the requested dismissal of all claims and counterclaims in the thalidomide patent cases. Celgene Corporation, headquartered in Summit, New Jers...  05/24/10 Celgene Corporation to Present at the 2010 Citi Global Health Care Conference SUMMIT, N.J., May 24, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Citi Global Health Care Conference on Wednesday, May 26, 2010 at 11:00 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated ...  05/21/10 More Than 100 Presentations and Posters Evaluating Celgene Products to Be Highlighted at Three Major Medical Meetings in June BOUDRY, Switzerland, May 21, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials evaluating Celgene products in blood cancers and solid tumors at the American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois from June 4-8. Additionally, clinical data will be presented on Celgene products in...  05/05/10 Celgene Corporation to Present at the Ninth Annual JMP Securities Research Conference SUMMIT, N.J., May 05, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Ninth Annual JMP Securities Research Conference on Monday, May 10, 2010 at 9:30 a.m. PT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an in...  04/29/10 Celgene Reports Record First Quarter 2010 Operating and Financial Results Record First Quarter Results Driven By Gains in Market Share and Duration of Therapy Across Global Markets REVLIMID(R) First Quarter Global Net Product Sales Increased 46% Y/Y VIDAZA(R) First Quarter Global Net Product Sales Increased 60% Y/Y Non-GAAP Diluted Earnings Per Share Increased 43% Y/Y SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2010 First Quarter Financial Results Year-Over-Year Non-GAAP...  04/29/10 Celgene Corporation Announces Senior Management Succession SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its senior management succession plan. As of the Company's annual meeting, scheduled on June 16, 2010, Dr. Sol J. Barer currently Chief Executive Officer, will be appointed Executive Chairman of the Board of Directors through December 31, 2010 and Robert J. Hugin, currently President and Chief Operating Officer, will be appointed Chief Executive Officer of Celgene Corporation. Dr. Barer has served a...  04/19/10 Celgene Corporation to Announce First Quarter 2010 Results on April 29, 2010 SUMMIT, N.J., Apr 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 29, 2010 at 9 a.m. ET to discuss the company's first quarter 2010 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated glo...  03/18/10 Celgene Corporation to Present at the Barclays Capital 2010 Global Healthcare Conference SUMMIT, N.J., Mar 18, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 at 10:45 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, ...  02/25/10 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J., Feb 25, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. On Wednesday, March 3, 2010, Celgene will present at the RBC Capital Markets 2010 Healthcare Conference at 8:00 a.m. ET. ...  01/28/10 Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals REVLIMID(R) Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q VIDAZA(R) Fourth Quarter Global Net Product Sales Increased 68% Y/Y and 13% Q/Q Full Year Non-GAAP Diluted Earnings Per Share Increased 33% Y/Y SUMMIT, N.J., Jan 28, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2009 Fourth Quarter Financial Results Year-Over-Y...  01/19/10 Celgene Corporation to Announce Fourth Quarter and Full-Year 2009 Results on January 28, 2010 SUMMIT, N.J., Jan 19, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 28, 2010 at 9 a.m. ET to discuss the company's fourth quarter and full-year 2009 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an ...  01/15/10 Celgene Completes Acquisition of Gloucester Pharmaceuticals Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 millionCommercial Launch of Novel HDAC Inhibitor, ISTODAX(R) (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010SUMMIT, N.J., Jan 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period u...  01/12/10 Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005 02) Evaluating Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Meets Primary Endpoint BOUDRY, Switzerland, Jan 12, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that the Intergroupe Francophone du Myelome and University Hospital of Toulouse, the sponsor of the study, reported that the independent Data and Safety Monitoring Committee, of the international Phase III, randomized, double-blind, multi-center clinical study (IFM 2005 02) evaluating REVLIMID(R) (lenalidomide) compared to placebo in multi...  01/11/10 Celgene Corporation Reviews 2009 Achievements and Announces 2010 Financial Outlook _ Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals î REVLIMID(R) Fourth Quarter Global Net Product Sales Increased Nearly 35% Y/Y î VIDAZA(R) Fourth Quarter Global Net Product Sales Increased Nearly 65% Y/Y î Full Year Non-GAAP Diluted Earnings Per Share Increased More Than 30 % Y/Y î Conducting 20 Phase III and Pivotal Clinical TrialsSUMMIT, N.J., Jan 11, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG)...  01/06/10 Celgene Corporation to Present at the 28th Annual JPMorgan Healthcare Conference SUMMIT, N.J., Jan 06, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 28th Annual JPMorgan Healthcare Conference on Monday, January 11, 2010 at 8:00 AM PST (11:00 AM EST) will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgen...  12/18/09 Initial Data from CALGB-Led Study of Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Reported Study showed statistically significant improvement in time to disease progressionSUMMIT, N.J., Dec 18, 2009 (BUSINESS WIRE) -- Celgene Corporation (Nasdaq:CELG) today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB). The investigational study evaluated REVLIMID(R) compared to placebo...  12/16/09 Celgene Corporation Elects Carrie S. Cox to Board of Directors SUMMIT, N.J., Dec 16, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced the election of Carrie S. Cox to the Company's Board of Directors. Ms. Cox is an experienced corporate director with a distinguished career in global healthcare. She has served as executive vice president and president of Schering-Plough's Global Pharmaceutical Business, one of the largest and most successful multi-national healthcare companies in the world. Before ...  12/15/09 Positive Phase IIb Topline Clinical Data for Celgene Oral Compound Apremilast (CC-10004) Reported for Patients with Moderate-to-Severe Psoriasis Placebo-controlled, four-arm study met its primary endpoint at 16 weeksStudy demonstrates PASI-75 of 41% for apremilast 30mg twice daily compared to 6% for placebo (p<0.001) at 16 weeks; apremilast was also generally well-toleratedPivotal phase III studies evaluatingapremilast in inflammatory conditions to begin in 2010SUMMIT, N.J., Dec 15, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) announced clinical data from an investigational Phase IIb, double-blind, placebo-control...  12/11/09 Celgene Corporation to Present at Deutsche Bank Securities Biotech Boston Confab Conference SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 11, 2009-- Celgene Corporation (NASDAQ:CELG) today announced its presentation at the Deutsche Bank Securities Biotech Boston Confab Conference on Tuesday, December 15, 2009 at 11:00 a.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquart...  12/07/09 Multi-Centre, Randomised, Controlled Study Results Evaluating the Clinical Potential of REVLIMID(R) in Patients with Smoldering Multiple Myeloma Presented at ASH After a Median Follow-Up of 14 Months, 4% of Patients with High-Risk Smoldering Multiple Myeloma Treated with REVLIMID-Based Therapy Had Progressed to Symptomatic Myeloma Compared to 34% of Patients not Offered REVLIMID-Based TherapyIn the Study, Oral Treatment with REVLIMID Demonstrated an 81% Response Rate in Patients with High-Risk Smoldering Multiple MyelomaBOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) announced that data evaluating com...  12/07/09 First Interim Analysis after Less Than 10-Months of Phase III Study Shows That Continuous REVLIMID(R) Therapy is Superior to Fixed Duration Regimens in Newly Diagnosed Elderly Multiple Myeloma Patients After less than ten months of median follow-up, elderly patients treated with MPR-R had a 50 percent reduction in the risk of disease progression or death compared to those who received MP aloneAt the first interim analysis, the median progression-free survival in the MPR-R arm was not reached, compared with a progression-free survival of 13 months in the MP arm (p<0.001)At first interim analysis, a statistically significant improvement in the overall response rate including VGPR and time to ...  12/07/09 Two Studies Evaluating the Clinical Potential of Pomalidomide for the Treatment of Multiple Myeloma Patients Refractory to Novel Therapies Presented at the American Society of Hematology Meeting BOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) today announced that its next-generation IMiD(R) immunomodulatory compound, pomalidomide was evaluated in two separate investigational trials of patients with multiple myeloma (MM) who were relapsed or refractory after treatment with REVLIMID(R) or REVLIMID and bortezomib. Data were presented at the 51st American Society of Hematology meeting in New Orleans, LA. ...  12/07/09 First Randomised Study Comparing All-Oral REVLIMID(R) Regimen Compared to Autologous Stem Cell Transplant Presented at ASH Study Reported Patients in Both Treatment Arms Achieved a 91% Progression-Free Survival Rate at 12 MonthsBOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either REVLIMID (lenalidomide), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following a...  12/07/09 Phase II Data Evaluating REVLIMID(R) + Rituximab in Relapsed Patients with Chronic Lymphocytic Leukaemia Presented at American Society of Hematology Combination Therapy of REVLIMID/Rituximab Achieved 64% Response Rate, in Patients Who Had Received Prior Treatments, Including RituximabBOUDRY, Switzerland, Dec 07, 2009 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ:CELG) announced that data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with relapsed chronic lymphocytic leukaemia (CLL) were presented during the 51st American Society of Hematology annual meeting in Ne...  12/07/09 Celgene to Acquire Gloucester Pharmaceuticals Commercial Launch of Novel HDAC Inhibitor, ISTODAX® (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted for Early 2010 ISTODAX Registration Special Protocol Assessment (SPA) Trial for Peripheral T-Cell Lymphoma (PTCL) - Accrual Expected to be Completed Early Next Year Acquisition Expected to be Neutral to Non-GAAP Diluted Earnings in 2010 and Accretive in 2011 SUMMIT, N.J. & C...  12/07/09 Celgene to Acquire Gloucester Pharmaceuticals Commercial Launch of Novel HDAC Inhibitor, ISTODAX® (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted for Early 2010 ISTODAX Registration Special Protocol Assessment (SPA) Trial for Peripheral T-Cell Lymphoma (PTCL) - Accrual Expected to be Completed Early Next Year Acquisition Expected to be Neutral to Non-GAAP Diluted Earnings in 2010 and Accretive in 2011     SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) a...  11/27/09 Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 27, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009 at 8:30 a.m. GMT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, N...  11/13/09 Celgene Corporation to Present at the Lazard Capital Markets 6th Annual Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 13, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquarter...  11/11/09 More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st American Society of Hematology Meeting SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 11, 2009-- Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from more than 200 recent and on-going clinical trials of Celgene products including REVLIMID®, VIDAZA®, THALOMID®, pomalidomide, ACE-011 and Amrubicin at the 51st Annual American Society of Hematology Meeting and Exposition from December 5-8, 2...  11/06/09 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 6, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. On Tuesday, November 10, 2009, Celgene will present at the Merriman Curhan Ford 6th Annual Inves...  10/30/09 Celgene Corporation to Present at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 30, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 10:15 a.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporati...  10/22/09 Celgene Reports Record Third Quarter 2009 Operating and Financial Results Record Third Quarter Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals REVLIMID® Third Quarter Global Sales Increased 31% Y/Y and 13% Q/Q REVLIMID U.S. Total Share Increased to Approximately 34%; Strong Share Gains in Second and Third Lines of Therapy in Europe VIDAZA® Third Quarter Global Sales Increased 62% Y/Y and 12% Q/Q First Interim Analysis o...  10/19/09 Updated Data from Randomized Controlled Phase II Study Evaluating Oral Apremilast in Psoriatic Arthritis Demonstrates Sustained Response at Six Months Study Extension Demonstrates ACR20 of 40% and 39% for 20mg BID and 40mg QD of Apremilast, Respectively, at 24 Weeks Activity and Safety Profile Supports Initiation of Pivotal Phase III Studies in the First Half of 2010 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 19, 2009-- Celgene Corporation (NASDAQ: CELG) announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of a...  10/13/09 Celgene Corporation to Announce Third Quarter Results on October 22, 2009 SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 13, 2009-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 22, 2009 at 9 a.m. EDT to discuss the company’s third quarter financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, i...  09/30/09 Celgene Corporation to Present at the JMP Securities Fourth Annual Healthcare Focus Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 30, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the JMP Securities Fourth Annual Healthcare Focus Conference on Monday, October 5, 2009 at 1:30 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headq...  09/17/09 Celgene Corporation to Present at the UBS Global Life Sciences Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 17, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 1:30 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New ...  09/11/09 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J.--(BUSINESS WIRE)--Sep. 11, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Monday, September 14, 2009, Celgene will present at the 2009 Morgan Stanley Global Healthcare U...  09/02/09 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J., Sep 02, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company. Wednesday, September 9, 2009, Celgene will present at the Thomas Weisel Partners Healthcare Conference 2009 at 8:00 a.m. ET....  08/05/09 Clinical Data Evaluating Amrubicin(R) as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 5, 2009-- Celgene Corporation (NASDAQ: CELG) today announced the presentation of final results from two company-sponsored studies of Amrubicin in relapsed small cell lung cancer (SCLC) at the 13th World Conference on Lung Cancer in San Francisco, Calif. The presentations included safety and efficacy data of two phase II studies of the next-generation therapy in second-line patients with SCLC both sensitive a...  08/05/09 VIDAZA Upgraded to Category 1 Based on Unprecedented Survival and Selected Preferred Treatment for Intermediate-2 and High-Risk Myelodysplastic Syndromes by the National Comprehensive Cancer Network (NCCN) in Its Clinical Practice Guidelines SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 5, 2009-- Celgene Corporation (Nasdaq: CELG) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology™ v1.2010 and has upgraded VIDAZA® to a Category 1 recommended treatment for patients with intermediate-2 and high-risk myelodysplastic syndromes (MDS). The NCCN consensus recommendation was based on the recent update to the ...  08/03/09 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 3, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Wednesday, August 5, 2009, Celgene will present at the BMO Capital Markets 9th Annual Focus on Healthcar...  07/23/09 Celgene Reports Record Second Quarter 2009 Operating and Financial Results SUMMIT, N.J.--(BUSINESS WIRE)--Jul. 23, 2009-- Celgene Corporation (NASDAQ:CELG): REVLIMID® Pivotal MM-015 Trial Exceeds Pre-Specified Interim Efficacy Endpoint in Newly Diagnosed Multiple Myeloma REVLIMID and VIDAZA® Gains in Market Share and Duration of Therapy Drive Second Quarter Record Results 2009 Second Quarter Financial Results Year-Over-Year: Non-GAAP Total Revenue Increased More...  07/09/09 Celgene Corporation to Announce Second Quarter Results on July 23, 2009 SUMMIT, N.J., Jul 09, 2009 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 23, 2009 at 9 a.m. EDT to discuss the company's second quarter financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global b...  07/07/09 Celgene Announces New Drug Application Filing for REVLIMID(R) in Japan BOUDRY, Switzerland--(BUSINESS WIRE)--Jul. 7, 2009-- Celgene International Sàrl (NASDAQ:CELG) today announced it has filed a New Drug Application (NDA) with the Japanese Ministry of Health, Labour and Welfare (MHLW) for REVLIMID (lenalidomide) in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approximately 11,000 people in Japan suffer from multiple myeloma and around 4...  06/17/09 Celgene Corporation to Present at Two Upcoming Investor Conferences SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 17, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Thursday, June 18, 2009, Celgene will present at the Jefferies 3rd Annual Healthcare Conference...  06/15/09 Celgene Announces Positive Top Line Data from Randomized Controlled Phase II Study of Apremilast in Psoriatic Arthritis SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 15, 2009-- Celgene Corporation (NASDAQ: CELG) announced the preliminary results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast - a novel, orally available small molecule that exhibits anti- inflammatory activities through the suppression of multiple pro-inflammatory mediators and cytokines - in adult patients with psoriatic arthritis (CC-10004-PSA-001). The ...  06/08/09 Innovative Therapy Improving Responses, Survival in Multiple Myeloma Patients According to Presentations at the 14th Congress of the European Hematology Association BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 8, 2009-- Celgene International Sàrl (NASDAQ: CELG) announced that data from multiple studies presented at the 14th Congress of the European Society of Hematology demonstrate that REVLIMID provides powerful and sustained responses in patients with multiple myeloma. These key presentations support the advantage of active long-term disease control along with manageable safety profiles, leading to unprec...  06/08/09 Presentations at the 14th Congress of the European Hematology Association Demonstrate VIDAZA(R) Benefits Patients with Myelodysplastic Syndromes BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 8, 2009-- Celgene International Sàrl (NASDAQ: CELG) announced that data presented at the 14th Congress of the European Society of Hematology demonstrate that treatment with VIDAZA significantly extends overall survival and helps patients with myelodysplastic syndromes (MDS) become or remain red blood cell transfusion independent. Patients who benefited included those with higher-risk MDS or acute myeloid leu...  06/04/09 Celgene Corporation to Present at Three Upcoming Investor Conferences SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 4, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at three upcoming investor conferences will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Tuesday, June 9, 2009, Celgene will present at the William Blair & Company Growth Stock Conference at ...  06/02/09 Data From REVLIMID(R) VIDAZA(R) and Amrubicin Clinical Trials Reported in Expanded Haematology and Oncology Indications Celgene Products Highlighted Across Multiple Diseases During 45th American Society of Clinical Oncology Meeting BOUDRY, Switzerland--(BUSINESS WIRE)--Jun. 2, 2009-- Celgene International Sàrl (NASDAQ: CELG) announced the results of multiple studies presented at the 45th American Society of Clinical Oncology meeting between May 30 and June 1, 2009 in Orlando, Florida. Key posters and presentations by clinical oncologists from around the world included studi...  05/26/09 59 Presentations and Posters Evaluating Celgene Products to Be Highlighted at the 45th American Society of Clinical Oncology Meeting SUMMIT, N.J.--(BUSINESS WIRE)--May. 26, 2009-- Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of multiple Celgene products in blood cancers and solid tumors at the 45th American Society of Clinical Oncology (ASCO) Meeting in Orlando, Florida from May 29 – June 2, 2009. For more information and for complete abs...  05/21/09 Celgene Corporation to Present at the Sanford C. Bernstein & Co. Strategic Decisions Conference 2009 SUMMIT, N.J.--(BUSINESS WIRE)--May. 21, 2009-- Celgene Corporation (NASDAQ:CELG) today announced its presentation at the Sanford C. Bernstein Strategic Decisions Conference 2009 on May 27, 2009 at 8:00 a.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit,...  05/18/09 Celgene Corporation to Present at the Eighth Annual JMP Securities Research Conference SUMMIT, NJ--(BUSINESS WIRE)--May. 18, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Eighth Annual JMP Securities Research Conference on Wednesday, May 20, 2009 at 9:00 a.m. PT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summi...  05/15/09 Celgene Corporation to Present at the Deutsche Bank 34th Annual Health Care Conference SUMMIT, N.J.--(BUSINESS WIRE)--May. 15, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19, 2009 at 8:10 a.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit...  05/11/09 Celgene Corporation to Present at Baird's 2009 Growth Stock Conference SUMMIT, N.J.--(BUSINESS WIRE)--May. 11, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at Baird’s 2009 Growth Stock Conference on Wednesday, May 13, 2009 at 8:55 a.m. CT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New J...  05/11/09 Celgene Corporation to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference SUMMIT, N.J.--(BUSINESS WIRE)--May. 11, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009 at 2:40 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, ...  04/30/09 Celgene Reports First Quarter 2009 Operating and Financial Results SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 30, 2009-- Celgene Corporation (NASDAQ: CELG): REVLIMID® Continues Gains in Multiple Myeloma Both in Market Share and Duration in US and International Markets REVLIMID Recommended by U.K. National Institute for Health and Clinical Excellence in Multiple Myeloma Through Final Appraisal Determination VIDAZA® Market Share Gains Cont...  04/27/09 Celgene Announces Share Repurchase Program SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 27, 2009-- Celgene Corporation (NASDAQ: CELG) today announced that the company's Board of Directors has authorized the repurchase of up to $500 million of the Company's common stock through April 2011. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene’s management and in accordance with the requirements of the Securities and ...  04/24/09 Celgene Corporation to Announce First Quarter Results on April 30, 2009 SUMMIT, N.J.--(BUSINESS WIRE)--Apr. 24, 2009-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 30, 2009 at 9 a.m. EDT to discuss the company’s first quarter financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an ...  04/23/09 REVLIMID(R) Receives Positive Final Appraisal Determination from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales BOUDRY, Switzerland--(BUSINESS WIRE)--Apr. 23, 2009-- Celgene International Sàrl (Nasdaq:CELG) today announced that the National Institute for Health and Clinical Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending REVLIMID, in combination with dexamethasone, within its licensed indication, as an option for the treatment of patients in England and Wales with multiple myeloma who have received two or more prior therapies. N...  03/31/09 Celgene Corporation to Present at the 4(th) Annual Citi Biotech Conference SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 31, 2009-- Celgene Corporation (NASDAQ: CELG) announced that Sol J. Barer, Ph.D., Chairman and Chief Executive Officer of Celgene will provide an overview of corporate developments and outlook for 2009 milestones at the 4th Annual Citi Biotech Day. During 2009, Celgene expects to advance multiple clinical, regulatory, commercial and financial initiatives in all areas of its global operations, underscored by the rec...  03/25/09 Celgene Corporation to Present at 4th Annual Citi Biotech Day SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 25, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 4th Annual Citi Biotech Day on Wednesday, April 1st, 2009 at 9:20 a.m. EDT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Corporation...  03/23/09 Celgene Corporation to Present at the Needham & Company, LLC Cancer Therapeutics: Today and Tomorrow Conference SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 23, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Needham & Company Cancer Therapeutics: Today and Tomorrow Conference on Thursday March 26, 2009 at 8:00 a.m. EDT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. David. W. Gryka, Senior Vice President and Chief Financial Officer, will provid...  03/13/09 Celgene Corporation to Present at the Cowen and Company 29th Annual Health Care Conference SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 13, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17, 2009 at 8 a.m. EDT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquarter...  03/06/09 Celgene Corporation to Present at the Barclays Capital Global Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Mar. 6, 2009-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Barclays Capital Global Healthcare Conference on Tuesday, March 10, 2009 at 9 a.m. EDT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, N...  02/26/09 70 Abstracts Evaluating the Potential of Celgene Products in Multiple Myeloma to Be Presented at the 12th International Myeloma Workshop Key Clinical Data Reinforce the Importance of Overall Survival and Long-Term Disease Control to Successful Myeloma Treatment SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 26, 2009-- Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from recent and ongoing clinical trials of multiple Celgene products at the 12th International Myeloma Workshop from February 26 – Ma...  02/17/09 Landmark Study Published in The Lancet Oncology Shows Celgene's Vidaza(R) Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid Leukaemia BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 17, 2009-- Celgene International Sàrl (Nasdaq:CELG) today announced the publication in the journal The Lancet Oncology of the results from AZA-001, the largest international, randomized, Phase III study ever conducted in patients with higher-risk myelodysplastic syndromes (MDS). The data indicate that VIDAZA (azacitidine) demonstrated a significant extension of overall survival compared to conventional care ...  02/06/09 Celgene Corporation to Present at the 11th Annual BIO CEO Investor Conference SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 11th Annual BIO CEO Investor Conference on Monday, February 9, 2009 at 2:45 p.m. EST will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene C...  01/30/09 REVLIMID(R) Receives Preliminary Positive Recommendation from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl (Nasdaq:CELG): NICE considers the benefits provided by REVLIMID to be life-extending and a cost-effective use of NHS resources NHS will fully fund the use of oral REVLIMID for 26 treatment cycles of 28 days per cycle (normally two years) for patients with previously treated multiple myeloma Celgene will fully fund the...  01/29/09 Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG): REVLIMID® #1 Therapy in Multiple Myeloma Worldwide European Launch of VIDAZA® Commencing REVLIMID U.S. Duration of Therapy Increased Greater Than 25 Percent Year-Over-Year to More Than 10 Months Global Expansion from Nearly 30 to More Than 65 Countries 2008 Fourth Quarte...  01/21/09 Celgene Corporation to Announce Fourth Quarter and Full-Year 2008 Results on January 29, 2009 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 21, 2009--Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 29, 2009 at 9 a.m. EST to discuss the company's fourth quarter and full-year 2008 financial and operational results. The webcast will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jerse...  01/12/09 Celgene Corporation Reviews 2008 Achievements and Announces 2009 Financial Outlook Significant Fourth Quarter Growth Propels REVLIMID(R) to the Global Market Leader in Multiple MyelomaSUMMIT, N.J., Jan 12, 2009 (BUSINESS WIRE) -- Exceptional 2008 Operating Performance Exceeding Annual Guidance with Record Revenue and Profit Growth -- Total Revenue for 2008 Increased to Approximately $2.233 Billion (Unaudited) -- REVLIMID Net Product Sales in 2008 Increased More Than 71 Percent Year-Over-Year to Approximately $1.324 Billion (Una...  01/09/09 Celgene Corporation to Present at the 27th Annual JPMorgan Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 9, 2009--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12, 2009 at 11 a.m. EST will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Co...  12/23/08 European Commission Grants VIDAZA(R) Full Marketing Authorization for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukaemia (AML) BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 23, 2008--Celgene International Sarl (Nasdaq:CELG): First and Only Epigenetic Cancer Therapy Proven to Significantly Extend Survival for Patients with Intermediate-2 and Higher-Risk MDS and AML First Approved Therapy Effective across Broad Range of MDS Subgroups, as well as Acute Myeloid Leukaemia (AML) with 20-30 percent Blasts and Multi-Lineage Dysplasia, as Classified by the World Health Organizat...  12/10/08 Promising Results from Two Trials Highlighting Developmental Oral IMiDS(R) Compound Pomalidomide Presented at the American Society of Hematology Meeting Pomalidomide Demonstrated Significant Activity in Treatment of Refractory Multiple Myeloma and Myelofibrosis BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 10, 2008--Celgene International Sarl (Nasdaq: CELG) today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis. The data were presented at the 50th Annual America...  12/09/08 Updated REVLIMID(R) Data in Newly-Diagnosed Multiple Myeloma Reports Unprecedented Three-Year Survival Rates in Phase III ECOG E4A03 Study REVLIMID and Low-Dose Dexamethasone As Continuous Therapy in the Front Line Setting is Associated With Robust Responses and is Well Tolerated According to Study BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 9, 2008--Celgene International Sarl (Nasdaq:CELG) today announced more mature data from clinical studies of REVLIMID (lenalidomide) in newly-diagnosed multiple myeloma were presented at a joint symposium of the American Society of Clinical Oncology (ASCO) and the Amer...  12/08/08 ASH Presentation of a Phase I Study of REVLIMID(R) and VIDAZA(R) in Higher-Risk MDS Reports Combination is Well-Tolerated and has High Activity Combination had a 39 Percent Complete Response and 72 Percent Overall Response BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) reported that results of a Phase I study presented today combining REVLIMID and VIDAZA in patients with higher-risk myelodysplastic syndromes (MDS) found that the combination of these two therapies is well tolerated and has high activity. The data were reported during the 50th Annual ...  12/08/08 VIDAZA(R) AZA-001 Study Reports Unprecedented Survival Benefit in Higher-Risk MDS Extends to AML Patients Subset Analysis of the AZA-001 Study Showed the Median Overall Survival was 24.5 Months with VIDAZA Compared to 16.0 Months with CCR (p=0.005) BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extends to patients with acute myeloid leukemia (AML). T...  12/08/08 Landmark Analysis Shows Continuous Treatment With REVLIMID(R) Plus Dexamethasone Significantly Increases Overall Survival in Multiple Myeloma Patients Analysis from Two Phase III REVLIMID Studies (MM-009 and MM-010) in Patients with Relapsed/Refractory Multiple Myeloma At Two Years, in Patients with at least Stable Disease, Nearly 94 Percent who Continued Therapy for More Than Ten Months Were Alive, Compared to Less Than 50 Percent who Discontinued Treatment Early BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) announced that data from a landmark analysis of patients with relapsed/...  12/08/08 ASH Presentation Shows Continued Treatment with VIDAZA(R) Improves Responses in Patients with Higher-Risk Myelodysplastic Syndromes 51 Percent Overall Response Rate (CR + PR) with Immediate and Chronic TherapyBOUDRY, Switzerland, Dec 08, 2008 (BUSINESS WIRE) -- Celgene International Sarl (NASDAQ: CELG) reports that an analysis presented today of a phase III international clinical trial (AZA-001) of higher-risk patients with myelodysplastic syndromes (MDS), demonstrated that continued treatment with VIDAZA (azacitidine) can improve patient responses. The data were presented at the 50th Annual ...  12/08/08 Study Presented at the American Society of Hematology Reports REVLIMID(R) Activity in Patients with Relapsed/Refractory Mantle-Cell Lymphoma Encouraging Response to REVLIMID Reported in International Phase II Study of Heavily Pretreated Patients with Specific Type of Non-Hodgkins Lypmhoma BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) announced updated clinical data from the NHL-003 study, a 200 patient open label, multi-center study of patients with relapsed/refractory mantle cell lymphoma (MCL) who had received at least one prior therapy. The subset ana...  12/08/08 Updated Data Evaluating Clinical Benefit Of REVLIMID(R) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma Presented At ASH REVLIMID Monotherapy Demonstrates Activity, Durability and Tolerability in This Subset of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients from International Phase II Study BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 8, 2008--Celgene International Sarl (NASDAQ: CELG) announced updated clinical data from an ongoing REVLIMID (lenalidomide) study of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) during the 50th Annual Meeting of the Americ...  12/08/08 Premier Cooperative Group in Adult Lymphoma Research Chooses REVLIMID(R) for Major Study in Disease's Largest Patient Population Celgene and GELA Announce Collaboration in an International, Randomized, Double-Blind, Placebo-Controlled, Phase III Maintenance Study in Diffuse Large B-Cell LymphomaBOUDRY, Switzerland & PARIS, Dec 08, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq: CELG) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA) today announced the initiation of an international randomized, double-blind, controlled Phase III study to evaluate the therapeutic potential of REVLI...  12/07/08 Two ASH Presentations Report REVLIMID(R) Activity and Tolerability in Patients with Previously Untreated Symptomatic Chronic Lymphocytic Leukemia Greater Than 90 Percent Disease Control Achieved Across All Evaluable PatientsBOUDRY, Switzerland, Dec 07, 2008 (BUSINESS WIRE) -- --Based on These Data Celgene is Actively Enrolling Patients in the CONTINUUM(TM) Trial, a Phase III Global SPA Study in Maintenance Setting and Plans to Open a Global Phase III Registration Trial in Untreated Symptomatic Elderly Patients Celgene International Sarl (NASDAQ: CELG) reported two REVLIMID (lenalidomide) Phase II studies, presented today at the 5...  11/17/08 Celgene Corporation to Present at the Lazard Capital Markets 5th Annual Healthcare Conference SUMMIT, N.J., Nov 17, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 5th Annual Healthcare Conference on Wednesday, November 19, 2008 at 9:30 a.m. EST will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the com...  11/11/08 128 Abstracts Evaluating Celgene Products to Be Presented at the 50th Annual American Society of Hematology Meeting - 35 Oral Presentations Highlighting Celgene Products Across Broad Range of Blood Cancers BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 11, 2008--Celgene International Sarl (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from recent and on-going clinical trials of multiple Celgene products at the 50th Annual American Society of Hematology Meeting and Exposition from December 6-9,...  11/10/08 Celgene Cellular Therapeutics Receives FDA Clearance for First Placenta-Derived Stem Cell Clinical Study -- Trial is First Application of Company's Proprietary Cell Therapy Product-- WARREN, N.J.--(BUSINESS WIRE)--Nov. 10, 2008--Celgene Cellular Therapeutics (CCT), a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's investigational new drug application to initiate a clinical trial using PDA001, an immunomodulatory therapy utilizing human placenta-derived stem...  11/07/08 Celgene Corporation to Present at the 2008 Credit Suisse Annual Health Care Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 7, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 2008 Credit Suisse Annual Health Care Conference on Wednesday, November 12, 2008 at 11:00 a.m. EST will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene Corporation, headquartered...  11/06/08 Celgene Corporation to Present at the Rodman & Renshaw Annual Global Investment Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 6, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11, 2008 at 9:30 a.m. EST will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Perry Karsen, Senior Vice President of Business Development, will provide an overview of the company. Celgene Corporation, headquartered...  10/31/08 Celgene Corporation to Present at the Oppenheimer 19th Annual Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 31, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Oppenheimer 19th Annual Healthcare Conference on Monday, November 3, 2008 at 10:40 a.m. EST will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Je...  10/24/08 Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML -- Committee for Medicinal Products for Human Use (CHMP) recommends approval of VIDAZA for treatment of MDS and AML BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sarl (Nasdaq:CELG) today announced that its cancer drug, VIDAZA(R) (azacitidine), has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: ...  10/23/08 Celgene Reports Record Third Quarter 2008 Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)-- 2008 Third Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 68 Percent to $587 Million; GAAP Total Revenue $592 Million REVLIMID(R) Net Product Sales Increased 72 Percent to $343 Million Global THALOMID(R)/Thalidomide Net Product Sales Reached $132 Million VIDAZA(R) Net Product Sales Achieved $64 Million, an Increase of 50 Percent Versus $42 Million in Q3 2007 VIDAZA Sales by ...  10/17/08 Celgene Corporation to Announce Third Quarter Results on October 23, 2008 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 23, 2008 at 9:00 a.m. EDT to discuss the Company's third quarter financial and operational results. The webcast will be available in the investor relations section of the Company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engage...  10/06/08 Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma BOUDRY, Switzerland, Oct 06, 2008 (BUSINESS WIRE) -- Celgene International SArl (NASDAQ: CELG) announced that its oral cancer drug REVLIMID (lenalidomide) has received marketing authorization approval from Health Canada for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. Multiple myeloma is the second most commonly diagnosed blood cancer worldwide. Approximately 6...  10/03/08 Celgene Corporation to Present at the Third Annual JMP Securities Healthcare Focus Conference SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Third Annual JMP Securities Healthcare Focus Conference on Tuesday, October 7, 2008 at 10:30 a.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Perry Karsen, Senior Vice President of Business Development, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New ...  09/19/08 Celgene Corporation to Present at the UBS 2008 Global Life Sciences Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 19, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the UBS 2008 Global Life Sciences Conference on Tuesday, September 23, 2008 at 8:00 a.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New J...  09/12/08 Celgene Corporation to Present at the Bank of America 38th Annual Investment Conference SUMMIT, N.J., Sep 12, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Bank of America 38th Annual Investment Conference on Tuesday, September 16, 2008 at 7:00 p.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene C...  09/12/08 Celgene Corporation to Present at Merrill Lynch Global Pharmaceutical Biotech and Medical Devices Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 12, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Merrill Lynch Global Pharmaceutical Biotech and Medical Devices Conference on Tuesday, September 16, 2008 at 11:10 a.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene...  09/05/08 Celgene Corporation to Present at Morgan Stanley Global Healthcare Unplugged Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 5, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 9, 2008 at 11:30 a.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene Corporation, headquart...  09/04/08 Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 4, 2008--Celgene Corporation (NASDAQ: CELG) today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy. A drug designated as a Fast Track product is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to provide a therapy where none exists or provide a ther...  09/03/08 Celgene Corporation to Present at the 3rd Annual Citi Biotech Day SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 3, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 9:00 a.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an ...  09/03/08 Celgene Corporation to Present at the Thomas Weisel Partners Experts in Growth Healthcare Conference 2008 SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 3, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Thomas Weisel Partners Experts in Growth Healthcare Conference 2008 on Friday, September 5, 2008 at 9:10 a.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Corporation, headqu...  09/02/08 Celgene Corporation to Present at the NewsMakers in the Biotech Industry Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 2, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the NewsMakers in the Biotech Industry Conference on Thursday, September 4, 2008 at 2:00 p.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene Corporation, headquartered i...  09/01/08 Journal of Clinical Oncology Reports REVLIMID(R) Demonstrates Activity against Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) BOUDRY, Switzerland--(BUSINESS WIRE)--Sept. 1, 2008--Celgene International Sarl (Nasdaq:CELG) today announced the publication of peer-reviewed data from a Phase II study of REVLIMID in relapsed or refractory aggressive non-Hodgkin's lymphoma in the Journal of Clinical Oncology. According to the data, REVLIMID, as an oral monotherapy, demonstrated activity in patients at an advanced stage of the disease who had received a median of four prior treatments and had limited treatment option...  08/21/08 VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS First and only drug to significantly extend survival for patients with higher-risk MDS First drug approved by FDA for treatment of all MDS risk categories First drug to achieve a transfusion independence rate of greater than 40 percent across all MDS risk categories First MDS drug approved with multiple routes of administration (SC and IV) SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 21, 2008--Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Foo...  08/05/08 Celgene Corporation to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 5, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Bank of America 2008 Specialty Pharmaceuticals Conference on Friday, August 8, 2008 at 8:45 a.m. EDT will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Perry Karsen, Senior Vice President of Business Development, will provide an overview of the company. Celgene Corporation, headquartered in S...  08/01/08 Celgene Corporation to Present at the BMO Capital Markets 2008 Focus on Healthcare Conference SUMMIT, N.J., Aug 01, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, 2008 at 8:30 a.m. EDT will be webcast live and will be available in the investor relations section of the company's website at www.celgene.com. Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New J...  07/24/08 Celgene Reports Record Second Quarter 2008 Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)--July 24, 2008-- 2008 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenues Increased 63 Percent to $566.6 Million; GAAP Total Revenues $571.5 Million REVLIMID(R) Net Product Sales Increased 80 Percent to $325.8 Million Global THALOMID(R)/Thalidomide Net Product Sales Reached $131.6 Million VIDAZA(R) Net Product Sales Achieved $59.7 Million Non-GAAP Operating Income Increased 60 ...  07/18/08 Celgene Corporation to Announce Second Quarter 2008 Results SUMMIT, N.J.--(BUSINESS WIRE)--July 18, 2008--Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 24, 2008 at 9:00am EDT to discuss the company's second quarter financial and operational results. The webcast will be available in the investor relations section of the company's website at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company en...  06/19/08 Celgene Corporation to Present at Jefferies 2nd Annual Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--June 19, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at Jefferies 2nd Annual Healthcare Conference on Wednesday, June 25, 2008 at 9:30 a.m. EDT will be webcast live and will be available in the investor relations section of the company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New...  06/17/08 Celgene Corporation to Present at William Blair & Company's 28th Annual Growth Stock Conference SUMMIT, N.J.--(BUSINESS WIRE)--June 17, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at William Blair & Company's 28th Annual Growth Stock Conference on Thursday, June 19, 2008 at 7:30 a.m. CDT will be webcast live and will be available in the investor relations section of the company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene Corporation, headquarte...  06/17/08 Clinical Data For REVLIMID(R) And VIDAZA(R) In Important Blood Cancers Presented at The 13th European Hematology Association Congress BOUDRY, Switzerland, Jun 17, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq: CELG): -- Study of VIDAZA in Higher-Risk MDS Patients Reports Improved Overall Survival -- New Analysis of Phase III Studies Shows REVLIMID Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple Myeloma -- Health Economic Analysis Reports that REVLIMID is a Cost Effective Treatment for Multiple Myeloma -- Preliminar...  06/16/08 REVLIMID(R) Data for Newly Diagnosed Multiple Myeloma Reported at a Satellite Symposium During the 13th European Hematology Association Congress COPENHAGEN, Denmark--(BUSINESS WIRE)--June 16, 2008--Data from the ECOG E4A03 and SWOG 0232 studies were reported at a Satellite Symposium and showed that newly diagnosed multiple myeloma patients who are eligible for a transplant, obtain better outcomes when treated with REVLIMID (lenalidomide) plus dexamethasone. The data were presented by Dr A. Stewart, from the Mayo Clinic at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark. These data from the ...  06/14/08 Health Economic Analysis Reports That Revlimid is a Cost Effective Treatment for Multiple Myeloma COPENHAGEN, Denmark--(BUSINESS WIRE)--June 14, 2008--Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced a significant survival gain regardless of the number of prior therapies they had received. The results showed that not only wa...  06/14/08 Preliminary Results from International Study Report That REVLIMID(R) Provides Responses for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma COPENHAGEN, Denmark--(BUSINESS WIRE)--June 14, 2008--Celgene International Sarl (Nasdaq:CELG) today announced that preliminary data from an international study of single agent REVLIMID (lenalidomide) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) were presented at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. In this study of heavily pretreated patients, 83 were eligible for response evaluation. An objective response was obs...  06/14/08 New Analysis of Phase III Studies Shows That REVLIMID(R) Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple Myeloma Longer Survival Than Previously DemonstratedCOPENHAGEN, Denmark, Jun 14, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq:CELG) today announced that according to data from a pooled study presented at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark, multiple myeloma patients taking REVLIMID(R) (lenalidomide) plus dexamethasone significantly increased their survival rates. A lifetime simulation yielded an estimated mean survival of 5.6 life-years with ...  06/13/08 Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival COPENHAGEN, Denmark--(BUSINESS WIRE)--June 13, 2008--Celgene International Sarl (Nasdaq:CELG) today announced results from a sub-analysis of a previously reported large, randomized phase III study (AZA-001), which showed that treatment with VIDAZA (azacitidine) prolonged overall survival for patients with high-risk myelodysplastic syndromes (MDS) when compared to conventional care regimens (CCR). This analysis evaluated a sub-group of patients (n=94) who were pre-selected to receive l...  06/13/08 VIDAZA(R) Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU Survival analysis pooled results from France, Germany, Italy, Spain, UK, Sweden, Greece and the Netherlands COPENHAGEN, Denmark--(BUSINESS WIRE)--June 13, 2008--Celgene International Sarl (Nasdaq:CELG) today announced that data showed VIDAZA (azacitidine) provides a significant overall survival benefit for patients with higher-risk myelodysplastic syndromes (MDS) regardless of whether patients were treated with low-dose Ara-C or best supportive care in the control arm...  06/10/08 Key Presentations of Celgene Products to Be Highlighted at the 13th European Hematology Association Congress BOUDRY, Switzerland, Jun 10, 2008 (BUSINESS WIRE) -- Celgene International Sarl (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers will present data from recent and on-going clinical trials of multiple Celgene products at the 13th European Hematology Association Congress in Copenhagen, Denmark from June 12 - 15, 2008. These presentations will highlight new efficacy and survival results, with important studies highlighting new health economic...  06/09/08 Celgene Corporation to Present at Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference SUMMIT, N.J.--(BUSINESS WIRE)--June 9, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008 at 10:00 a.m. EDT will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. C...  06/09/08 Celgene Corporation to Present at Goldman Sachs 29th Annual Global Healthcare Conference SUMMIT, N.J., Jun 09, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Goldman Sachs 29th Annual Global Healthcare Conference on Wednesday, June 11th, 2008 at 10:00 a.m. PDT will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. Sol Barer, Ph.D., Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New...  06/03/08 Study of VIDAZA(R) in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival SUMMIT, N.J.--(BUSINESS WIRE)--June 3, 2008--Celgene Corporation (Nasdaq:CELG) today announced updated results from a Phase III international clinical trial of VIDAZA in patients with myelodysplastic syndromes demonstrated an extension of overall survival compared to conventional care regimens (CCR). The data were presented at the 44th Annual American Society of Clinical Oncology meeting in Chicago, IL. In the study, the two-year survival rate for patients treated with VIDAZA was...  06/02/08 Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population SUMMIT, N.J.--(BUSINESS WIRE)--June 2, 2008--Celgene Corporation (Nasdaq:CELG) today announced physicians from leading medical centers presented data from two Phase II clinical studies of amrubicin in patients with extensive-disease small-cell lung cancer (SCLC) either sensitive to platinum-based first-line therapy or refractory to platinum-based first-line therapy. Results of the studies demonstrated improved overall response rates that compare favorably with topotecan, as well as no...  06/02/08 Celgene Withdraws European Union (EU) Marketing Authorization Application for Lenalidomide in Deletion-5Q Myelodysplastic Syndromes BOUDRY, Switzerland--(BUSINESS WIRE)--June 2, 2008--Celgene International Sarl (NASDAQ: CELG) announced that, following discussions with the European Medicines Agency (EMEA) and the EMEA's Committee for Medicinal Products for Human use (CHMP), it has withdrawn its Marketing Authorization Application (MAA) for Lenalidomide - Celgene Europe (lenalidomide), which was intended for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplasti...  06/01/08 Updated REVLIMID(R) Results Presented In Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) at ASCO BOUDRY, Switzerland, Jun 01, 2008 (BUSINESS WIRE) -- Celgene International Sarl (Nasdaq:CELG) today announced preliminary data were presented from an international study of single agent REVLIMID in relapsed/refractory non-Hodgkin's lymphoma (NHL-003, Abstract #8509). The data was presented at the 44th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago, IL. In this study of heavily pretreated patients, 83 were eligible for response evaluation. An objective response was o...  06/01/08 Updated REVLIMID(R) Data Presented in Newly Diagnosed Multiple Myeloma Presented at the 2008 American Society of Clinical Oncology (ASCO) Meeting In a four-month landmark analysis of ECOG Phase III study E4A03, patients who continued on treatment of REVLIMID plus low-dose dexamethasone (Rd) achieved a two-year overall survival rate of 93 percent In the same landmark analysis, patients who went on to autologous stem cell transplant achieved the same two-year survival rate of 93 percent Patients in the landmark analysis who received Rd achieved an overall response rate of ...  05/26/08 Celgene Corporation to Present at FBR Capital Markets Spring Investor Conference SUMMIT, N.J., May 26, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the FBR Capital Markets Spring Investor Conference on Wednesday, May 28, 2008 at 11:15 a.m. EDT will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. Perry Karsen, Senior Vice President of Business Development, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey...  05/20/08 Celgene Corporation to Present at 2008 Citi Investment Research Global Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--May 20, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 2008 Citi Investment Research Global Healthcare Conference on Thursday, May 22, 2008 at 3:30pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, N...  05/19/08 Celgene Corporation to Present at NASDAQ OMX 21st Investor Program SUMMIT, N.J.--(BUSINESS WIRE)--May 19, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the NASDAQ OMX 21st Investor Program on Wednesday, May 21, 2008 at 8:30am BST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, ...  05/19/08 Celgene Corporation to Present at The Seventh Annual JMP Securities Research Conference SUMMIT, N.J.--(BUSINESS WIRE)--May 19, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at The Seventh Annual JMP Securities Research Conference on Wednesday, May 21, 2008 at 10:30am PDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Perry Karsen, Senior Vice President of Business Development, will provide an overview of the company. Celgene Corporation, headquartered in Summit, N...  05/16/08 75 Abstracts Evaluating Celgene Products to Be Presented at The 44th American Society of Clinical Oncology Meeting SUMMIT, N.J.--(BUSINESS WIRE)--May 16, 2008--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of multiple Celgene products in blood cancers and solid tumors at the 44th American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois from May 31 - June 3, 2008. For more information and for complete abstracts, please visit www.asco.org. Celgene...  05/12/08 Celgene Corporation to Present at Bank of America's 2008 Healthcare Conference SUMMIT, N.J., May 12, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at Bank of America's 2008 Healthcare Conference on Wednesday, May 14, 2008 at 4:40 p.m. PDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the Company. Celgene Corporation, headquartered in Summit, New Jersey, is an integ...  05/09/08 Celgene Corporation to Present at Baird's 2008 Growth Stock Conference SUMMIT, N.J.--(BUSINESS WIRE)--May 9, 2008--Celgene Corporation (NASDAQ: CELG) today announced its presentation at Baird's 2008 Growth Stock Conference on Tuesday, May 13, 2008 at 11:50 a.m. CDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is...  05/08/08 Celgene Reports Record First Quarter 2008 Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)--May 8, 2008-- 2008 First Quarter Financial Results Year-Over-Year Non-GAAP Total Revenues Increased 57 Percent to $461.0 Million; GAAP Total Revenues $462.6 Million REVLIMID(R) Net Product Sales Increased 96 Percent to $286.8 Million THALOMID(R) Net Product Sales Reached $113.9 Million Non-GAAP Operating Income Increased 96 Percent to $188.4 Million; GAAP Operating Loss $1.63 Billion due to Acquisition ...  05/02/08 Celgene Cellular Therapeutics Announces Clinical Transplant of Human Placenta-Derived Stem Cells -- First Application is Pediatric Patient with Acute Lymphoblastic Leukemia (ALL) -- -- Study in Collaboration with Louisiana State University Children's Hospital and Morgan Stanley Children's Hospital of NewYork-Presbyterian and Columbia University Medical Center WARREN, N.J.--(BUSINESS WIRE)--May 2, 2008--Celgene Cellular Therapeutics (CCT), a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced the cli...  04/30/08 Celgene Corporation to Announce First Quarter Results on May 8, 2008 SUMMIT, N.J.--(BUSINESS WIRE)--April 30, 2008--Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, May 8, 2008 at 9:00 am EDT to discuss the Company's first quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company eng...  04/29/08 Celgene Corporation to Present at Morgan Stanley Healthcare Unplugged Conference SUMMIT, N.J.--(BUSINESS WIRE)--April 29, 2008--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Morgan Stanley Healthcare Unplugged Conference on Thursday, May 1, 2008 at 3:40 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New J...  04/21/08 Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union BOUDRY, Switzerland--(BUSINESS WIRE)--April 21, 2008--Celgene International Sarl (NASDAQ: CELG) announced that Thalidomide Pharmion has been granted full marketing authorization by the European Commission for use in combination with melphalan and prednisone as a treatment for patients with newly diagnosed multiple myeloma. In June 2007, the European Commission granted the Company's REVLIMID(R) full marketing authorization as the first oral treatment in more than 40 years for patients ...  04/11/08 Amrubicinis Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer BOUDRY, Switzerland--(BUSINESS WIRE)--April 11, 2008--Celgene International Sarl (NASDAQ: CELG) today announced that amrubicin hydrochloride has been designated as an orphan medicinal product by the European Commission (EC) for the treatment of small cell lung cancer following the favorable opinion of the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP). Criteria for designation of orphan medicinal product require that the product be intended for...  04/07/08 Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma BOUDRY, Switzerland, Apr 07, 2008 (BUSINESS WIRE) -- Celgene International Sarl (NASDAQ: CELG) today announced the Australian Therapeutic Goods Administration (TGA) approved a supplemental filing granting Thalidomide Pharmion marketing approval for use in combination with melphalan and prednisone for patients with untreated multiple myeloma or ineligible for high dose chemotherapy. Additionally, Thalidomide Pharmion was granted marketing approval in combination with dexamethasone for induc...  03/25/08 Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer SUMMIT, N.J.--(BUSINESS WIRE)--March 25, 2008--Celgene Corporation (NASDAQ: CELG) today announced that Amrubicin has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer. FDA's Orphan Drug Act was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions that are rare and affect 200,000 persons or ...  03/14/08 Celgene Corporation to Present at Lehman Brothers Global Healthcare Conference SUMMIT, N.J., Mar 14, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Lehman Brothers Global Healthcare Conference on Tuesday, March 18, 2008 at 5:15 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an...  03/13/08 Celgene Corporation to Present at Cowen Health Care Conference SUMMIT, N.J.--(BUSINESS WIRE)--March 13, 2008--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Cowen Health Care Conference on Monday, March 17, 2008 at 1:45 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, ...  03/10/08 Celgene Corporation to Present at Bear Stearns London Healthcare Conference SUMMIT, N.J., Mar 10, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Bear Stearns London Healthcare Conference on Thursday, March 13, 2008 at 8:45 am GMT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an inte...  03/07/08 Celgene Completes $2.9 Billion Acquisition of Pharmion Acquisition moves Celgene closer to becoming a leading global hematology/oncology company Combined company will bring together three innovative disease-altering therapies and a deep pipeline in cancer and inflammation SUMMIT, N.J.--(BUSINESS WIRE)--March 7, 2008--Celgene Corporation (NASDAQ: CELG) today announced it has closed its $2.9 billion acquisition of Pharmion Corporation. Pharmion shareholders will rec...  03/06/08 Celgene and Pharmion Announce Shareholder Vote in Favor of Acquisition of Pharmion Acquisition moves Celgene closer to becoming a leading global hematology/oncology company Combined company will bring together three innovative disease-altering therapies and a deep pipeline in cancer and inflammation SUMMIT, N.J. & BOULDER, Colo.--(BUSINESS WIRE)--March 6, 2008--Celgene Corporation (NASDAQ: CELG) and Pharmion Corporation (NASDAQ: PHRM) today announced that Pharmion's shareholders approved the...  02/19/08 Lenalidomide (REVLIMID(R)) Receives Orphan Drug Status in Japan for Multiple Indications Ministry of Health, Labour and Welfare grants designation in both deletion 5q MDS and previously treated multiple myeloma BOUDRY, Switzerland--(BUSINESS WIRE)--Feb. 19, 2008--Celgene International Sarl (NASDAQ: CELG) announced that lenalidomide (CC-5013) has been granted orphan drug status by Japan's Ministry of Health, Labour and Welfare (MHLW) for two different indications: the treatment of both anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) as...  02/04/08 Celgene Corporation to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference SUMMIT, N.J., Feb 04, 2008 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced that its presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, Feb. 6, 2008 at 8:40 am EST will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquar...  02/04/08 Clinical Data Reported on Celgene Compound Apremilast (CC-10004) Evaluating Efficacy, Safety and Quality of Life Improvement for Psoriasis Patients Updated results presented at 66th American Academy of Dermatology Meeting SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 4, 2008--Celgene Corporation (NASDAQ: CELG) announced that clinical data from a completed Phase II study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis were presented for the first time at the 66th American Academy of Dermatology meeting in San Antonio, Texas on Saturday, Feb. 2, 2008. Kim Papp, M.D.,...  01/31/08 Celgene Reports Record Fourth Quarter and Full Year 2007 Product Sales and Operating Profits 2007 Fourth Quarter Financial Results Year-Over-Year: Total Revenue Increased 51 Percent to $414.6 Million REVLIMID® Net Product Sales Increased 100 Percent to $247.4 Million THALOMID® Net Product Sales Increased to $112.6 Million Adjusted Operating Income Increased 97 Percent to $156.5 Million Adjusted Net Income Increased 78 Percent to $132.8 Million Adjusted Earnings Per Share Increased 72 Percent to $0.31 Per Diluted Share 2007 Full Year Financial Re...  01/28/08 Celgene Corporation to Present at Wachovia Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 28, 2008--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Wachovia Healthcare Conference on Thursday, January 31, 2008 at 1:30 pm EST will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated gl...  01/28/08 German Federal Cartel Office Clears Celgene to Acquire Pharmion SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 28, 2008--Celgene Corporation (NASDAQ: CELG) and Pharmion Corporation (NASDAQ: PHRM) announced that the Bundeskartellamt, Germany's Federal Cartel Office in charge of reviewing the antitrust aspects of mergers and acquisitions, has cleared Celgene's pending acquisition of Pharmion Corporation. As previously announced on January 3, 2008, the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired ...  01/25/08 Celgene Corporation to Announce Fourth Quarter and Year-End 2007 Results on January 31, 2008 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 25, 2008--Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, January 31, 2008 at 9:00 am EST to discuss the Company's fourth quarter and year-end operational results. The webcast will be available in the investor relations section of the Company's website at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company...  01/24/08 Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory Developments in Multiple Myeloma and Deletion 5Q Myelodysplastic Syndromes REVLIMID in combination with dexamethasone receives Marketing Authorisation Approval for relapsed/refractory multiple myeloma in Australia REVLIMID receives conditional Marketing Authorisation Approval for deletion 5q MDS in Canada Lenalidomide - Celgene Europe receives Negative Opinion on Marketing Authorisation Application for deletion 5q MDS in European Union (EU) BOUDRY, Sw...  01/06/08 Celgene Corporation Reviews 2007 Achievements and Announces 2008 Financial Outlook SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 6, 2008-- Company Reports Record Operating Performance in 2007 Driven by Extraordinary Revenue and Profit Growth Total Revenue for 2007 Increased More Than 50 Percent Year-Over-Year to Approximately $1.4 Billion (Unaudited) REVLIMID(R) Net Product Sales in 2007 Increased More Than 140 Percent Year-Over-Year to a Range of $770-775 Million (Unaudited) REVLIMID Net Product Sales in Fourth Quarter 2007 Incre...  01/03/08 Celgene/Pharmion Hart-Scott-Rodino (HSR) Thirty Day Waiting Period Expires SUMMIT, N.J. & BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3, 2008--Celgene Corporation (NASDAQ: CELG) and Pharmion Corporation (NASDAQ: PHRM) today jointly announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired without the United States Federal Trade Commission requesting additional information with regard to Celgene's pending acquisition of Pharmion. The Companies anticipate that the transaction will close in April of...  12/20/07 Celgene Will Provide Fourth Quarter and Full-Year 2007 Guidance at the 26th Annual JP Morgan Healthcare Conference Company will provide full-year 2008 guidanceSUMMIT, N.J., Dec 20, 2007 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced Chief Executive Officer Sol J. Barer, Ph.D., will present fourth quarter and full-year 2007 and 2008 guidance during a presentation at the JP Morgan Healthcare Conference on Monday, January 7, 2008 at 11:30 am EST. The event will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. Celge...  12/05/07 113 Abstracts Evaluating Celgene Products to Be Presented at the 49th American Society of Hematology Meeting Sixty-five Abstracts Investigating REVLIMID(R) in a Broad Range of Hematological Cancers SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 5, 2007--Celgene Corporation (NASDAQ: CELG) announced today that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of REVLIMID (lenalidomide) at the American Society of Hematology 49th Annual Meeting, considered the premier educational and scientific event in the hema...  11/30/07 Celgene Corporation to Present at BMO Capital Markets Focus on Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 30, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the BMO Capital Markets Focus on Healthcare Conference on Tuesday, December 4, 2007 at 9:00 am EST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New ...  11/30/07 Lenalidomide (REVLIMID(R)) Receives Orphan Medicinal Product Designation from the European Commission for Chronic Lymphocytic Leukemia BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 30, 2007--Celgene International Sarl (NASDAQ: CELG) announced that lenalidomide (REVLIMID) has been granted orphan medicinal product designation by the European Commission (EC) for treatment of chronic lymphocytic leukemia (CLL) following the favorable opinion of the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP). Orphan medicinal product designation is granted by the EC to promote development of drugs ...  11/21/07 Two Major Phase III Studies Report Oral REVLIMID(R) (Lenalidomide) Plus Dexamethasone Shows Increased Overall Survival Advantage to Dexamethasone Plus Placebo in Previously Treated Multiple Myeloma Patients in The New England Journal of Medicine BOUDRY, Switzerland--(BUSINESS WIRE)--Nov. 21, 2007--The New England Journal of Medicine today published updated clinical data from two Celgene Corporation (NASDAQ: CELG)-sponsored multi-centered, randomized, double-blind, placebo-controlled Phase III pivotal studies evaluating lenalidomide plus dexamethasone in previously treated multiple myeloma patients. The updated clinical data from the pivotal International Phase III trial reported median time to disease progression in patie...  11/21/07 Updated REVLIMID(R) (Lenalidomide) Plus Dexamethasone Data in Previously Treated Multiple Myeloma Reported in The New England Journal of Medicine Major Phase III Studies Report Oral REVLIMID Plus Dexamethasone Shows Time to Disease Progression and Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 21, 2007--The New England Journal of Medicine today published updated clinical data from a Celgene Corporation (NASDAQ: CELG)-sponsored multi-centered, randomized, double-blind, placebo-controlled Phase III pivotal study evaluating lenalidomide plus dexa...  11/21/07 Celgene Corporation to Present at Lazard Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 21, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Lazard Capital Markets 4th Annual Healthcare Conference on Tuesday, November 27, 2007 at 1:30 pm EST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer, will provide an overview of the company. Celgene Corporation, headquartered in Summi...  11/20/07 Celgene Corporation to Present at Piper Jaffray Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 20, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Piper Jaffray 19th Annual Healthcare Conference on Tuesday, November 27, 2007 at 12:00 pm EST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquartered ...  11/19/07 REPEAT/Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock Pharmion's Oncology Portfolio Further Strengthens Celgene's Pipeline Accelerates Celgene's Revenue and Earnings Growth, Accretive in 2009 and Beyond SUMMIT, N.J. & BOULDER, Colo.--(BUSINESS WIRE)--Nov. 19, 2007--Celgene Corporation (Nasdaq: CELG) and Pharmion Corporation (Nasdaq: PHRM) today jointly announced the signing of a definitive merger agreement pursuant to which Celgene has agreed to acquire Pharmion. Under the terms of the merger agreement, Celgene will acquire all...  11/12/07 Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma NEUCHATEL, Switzerland--(BUSINESS WIRE)--Nov. 12, 2007--Celgene International Sarl (NASDAQ: CELG) announced that its oral cancer drug REVLIMID (lenalidomide) has received recommendation for approval from the Australian Drug Evaluation Committee (ADEC) for use in combination with dexamethasone as a treatment for patients with multiple myeloma whose disease has progressed after one therapy. Multiple myeloma is the second most commonly diagnosed blood cancer. ADEC's recommendation fo...  11/09/07 Celgene Corporation to Present at Citibank Biotech Day SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 9, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Citibank Biotech Day on Monday, November 12, 2007 at 11:30 am EST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated globa...  11/08/07 Celgene Corporation to Present at JMP Securities Healthcare Focus Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 8, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the JMP Securities Healthcare Focus Conference on Tuesday, November 13, 2007 at 9:00 am EST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jers...  11/07/07 Celgene Corporation to Present at Credit Suisse Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 7, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Credit Suisse Annual Healthcare Conference on Tuesday, November 13, 2007 at 2:00 pm MST (12:00 pm EST) will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headqu...  11/01/07 Celgene Corporation to Present at Rodman & Renshaw Global Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Nov. 1, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Global Healthcare Conference on Monday, November 5, 2007 at 11:40 am EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Celgene senior management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey...  10/25/07 Celgene Reports Record Third Quarter Product Sales and Operating Profits SUMMIT, N.J.--(BUSINESS WIRE)--Oct. 25, 2007-- 2007 Third Quarter Financial Results Year-Over-Year: Total Revenue Increased 43 Percent to $350 Million Product Sales Increased 48 Percent to $331 Million REVLIMID(R) Net Product Sales Increased 97 Percent to $199 Million THALOMID(R) Net Product Sales Increased to $111 Million Adjusted Operating Income Increased 84 Percent to $146 Million Adjusted Net Income Increased 109 Percent to ...  10/19/07 Celgene Corporation to Announce Third Quarter Results on October 25, 2007 SUMMIT, N.J., Oct 19, 2007 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 25, 2007 at 9:00 am EDT to discuss the Company's third quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged ...  09/20/07 Celgene Corporation to Present at UBS Global Life Sciences Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 20, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the UBS 2007 Global Life Sciences Conference on Tuesday, September 25, 2007 at 2:30 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquartered in Sum...  09/18/07 Celgene Corporation to Present at Merrill Lynch Global Pharmaceutical Biotech & Medtech Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 18, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference on Thursday, September 20, 2007 at 11:20 am BST (6:20 am EDT) will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene C...  09/17/07 Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia Clinical Data from Ongoing Studies Evaluate REVLIMID in Relapsed or Refractory Chronic Lymphocytic Leukemia BOUDRY, Switzerland--(BUSINESS WIRE)--Sept. 17, 2007--Celgene Corporation (NASDAQ: CELG) announced that clinical data from two ongoing REVLIMID studies in Chronic Lymphocytic Leukemia (CLL) were reported during the 12th International Workshop on Chronic Lymphocytic Leukemia in London on Saturday, September 15, 2007. Chronic Lymphocytic Leukemia is a hematological...  09/06/07 Celgene Corporation Will Present at the Bear Stearns 20th Annual Healthcare Conference SUMMIT, N.J.--(BUSINESS WIRE)--Sept. 6, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Bear Stearns & Co. Inc. 20th Annual Healthcare Conference on Monday, September 10, 2007 at 4:30pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol. J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summ...  09/04/07 Oral Cancer Drug REVLIMID® Receives Swissmedic Approval in Switzerland For Treatment of Multiple Myeloma SUMMIT, NJ – (September 4, 2007) – Celgene International Sàrl (NASDAQ: CELG) announced today that it's oral cancer drug, REVLIMID (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. This approval represents the first regulatory approval for Celgene in Switzerland, and REVLIMID represents the first oral ther...  08/31/07 Celgene Corporation to Present at the NewsMakers in the Biotech Industry Conference SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 31, 2007--Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the NewsMakers in the Biotech Industry Conference on Thursday, September 6, 2007 at 3:00 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an i...  08/31/07 Celgene Corporation to Present at Thomas Weisel Partners Healthcare Conference SUMMIT, N.J., Aug 31, 2007 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) announced today that its presentation at the Thomas Weisel Partners Healthcare Conference on Thursday, September 6, 2007 at 1:30 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, i...  08/23/07 Celgene Corporation Elects Ernest Mario to Board of Directors SUMMIT, N.J.--(BUSINESS WIRE)--Aug. 23, 2007--Celgene Corporation (NASDAQ: CELG) announced the election of Ernest Mario, Ph.D. to the Company's Board of Directors. Dr. Mario is an experienced corporate director with a distinguished career in global healthcare. Dr. Mario has served as Deputy Chairman and Chief Executive of Glaxo Holdings plc., one of the largest and most successful multi-national healthcare companies in the world. Also, Dr. Mario served as Chairman and Chief Executive ...  07/26/07 Celgene Reports Record Second Quarter Product Sales and Operating Profits 2007 Second Quarter Financial Results Year-Over-Year: Total Revenue Increased 76 Percent To $348 Million Product Sales Increased 81 Percent To $319 Million REVLIMID(R) Net Product Sales Increased 187 Percent To $181 Million THALOMID(R) Net Product Sales Totaled $118 Million Adjusted Operating Income Increased 143 Percent To $130 Million Adjusted Net Income Increased 160 Percent To $110 Million Adjusted Earnings Per...  07/10/07 Celgene Corporation to Announce Second Quarter Results on July 26, 2007 SUMMIT, N.J.--(BUSINESS WIRE)--July 10, 2007--Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 26, 2007 at 9:00 am EDT to discuss the Company's second quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company e...  06/15/07 REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union SUMMIT, N.J., June 19 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by the European Commission for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. This approval represents the first regulatory approval for Celgene in Europe, and REVLIMID represents the first breakthrough oral cancer therapy in Europe fo...  06/08/07 Celgene Corporation Will Present at the Goldman Sachs Global Healthcare Conference SUMMIT, N.J., June 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Goldman Sachs 28th Annual Global Healthcare Conference on Wednesday, June 13, 2007 at 2:00 pm PT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol. J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Su...  06/07/07 Celgene Corporation Will Present at the Needham Biotechnology & Medical Technology Conference SUMMIT, N.J., June 7 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Needham Biotechnology & Medical Technology Conference on Wednesday, June 13, 2007 at 8:30 am ET will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquarter...  05/22/07 Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Franchise SUMMIT, N.J., May 22 -- Celgene Corporation (Nasdaq: CELG) announced its plans to advance the development of leading oral anti-inflammatory candidates across a broad range of inflammatory diseases. CC-10004 (apremilast), an oral TNF antagonist and anti-inflammatory agent has demonstrated significant activity and an excellent side effect profile in a placebo contr...  05/15/07 SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone SWOG Action Based on Results from ECOG Phase III Study (E4A03) SUMMIT, N.J., May 15 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the Southwest Oncology Group (SWOG) has permanently closed enrollment in a federally funded clinical trial. The Phase III randomized controlled study (S0232) compared a standard drug therapy, dexamethasone, with a combined therapy of dexamethasone plus REVLIMID (lenalidomide) for patients newly diagnosed with multiple my...  05/14/07 Celgene Corporation Will Present at the Citigroup Global Healthcare Conference SUMMIT, N.J., May 14 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Citigroup Global Healthcare Conference on Tuesday, May 22, 2007 at 1:30 pm ET will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an int...  05/10/07 Celgene Corporation Will Present at the JMP Securities Research Conference SUMMIT, N.J., May 10 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the JMP Securities Research Conference on Monday, May 21, 2007 at 3:30 pm PDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Celgene senior management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceut...  05/08/07 Celgene Corporation Will Present at the Acumen BioFin Rodman & Renshaw Global Healthcare Conference SUMMIT, N.J. May 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Acumen BioFin Rodman & Renshaw Global Healthcare Conference on Tuesday, May 15, 2007 at 12:35 pm CEST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in S...  05/03/07 Celgene Reports First Quarter Record Operating Performance and Significant Global Clinical and Regulatory Progress 2007 First Quarter Financial Results Year-Over-Year: -- Total Revenue Increased 61 Percent To $293 Million -- Product Sales Increased 68 Percent To $270 Million -- REVLIMID(R) Net Product Sales Increased 351 Percent To $146 Million -- THALOMID(R) Net Product Sales Totaled $106 Million -- Adjusted Operating Income Increased 103 Percent To $96 Million -- Adjusted Net Income Increased 154 Percent To $86 Million -- Adjusted Earnings Per Share In...  04/26/07 Celgene Corporation Will Present at the UBS Global Generic and Specialty Pharmaceuticals Conference SUMMIT, N.J., April 26 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the UBS Global Generic and Specialty Pharmaceuticals Conference on Wednesday, May 9, 2007 at 11:30 am ET will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in...  04/25/07 Celgene Corporation Will Present at the Baird Growth Stock Conference SUMMIT, N.J., April 25 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at Baird's 2007 Growth Stock Conference on Tuesday, May 8, 2007 at 10:40 am CT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jerse...  04/24/07 Celgene Corporation Will Present at the Morgan Stanley Global Healthcare Unplugged Conference SUMMIT, N.J., April 24 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Morgan Stanley Global Healthcare Unplugged Conference on Friday, May 4, 2007 at 11:00 a.m. ET will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in...  04/16/07 Celgene Corporation to Announce First Quarter Results on May 3, 2007 SUMMIT, N.J., April 16 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) senior management will host a conference call and live audio webcast on Thursday, May 3, 2007 at 9:00 am EDT to discuss the Company's first quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at http://www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical c...  04/04/07 ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma SUMMIT, N.J., April 4 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the Eastern Cooperative Oncology Group (ECOG) has reported that its Data Monitoring Committee's (DMC) review of preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma has found that the use of a low dose of dexamethasone (Decadron) in combination with lenalidomide suggests survival advantage for patients when compared to the higher, s...  03/23/07 Oral Cancer Drug REVLIMID® Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency SUMMIT, N.J., March 23 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its innovative oral cancer drug REVLIMID (lenalidomide) has received a positive opinion from the European Medicines Agency (EMEA) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. The EMEA's Committee for Medicinal Products for Human Use (CHMP), which reviews applications for all 27 Member States...  03/07/07 Celgene Corporation Will Present at the Cowen and Company 27th Annual Healthcare Conference SUMMIT, N.J., March 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Cowen and Company Healthcare Conference on Monday, March 12, 2007 at 2:25 pm ET will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. David W. Gryska, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, head...  02/16/07 Celgene Corporation Will Present at The Bear Stearns London Healthcare Conference SUMMIT, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Bear Stearns London Healthcare Conference on Tuesday, February 27, 2007 at 9:20 am GMT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Aart Brouwer, President of Celgene International will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, ...  02/08/07 Celgene Corporation Will Present at the BIO CEO & Investor Conference SUMMIT, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the BIO CEO & Investor Conference 2007 on Monday, February 12, 2007 at 11:00 am ET will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, ...  02/01/07 Celgene Reported Exceptional Operating Performance Driven by Record Revenue and Profits 2006 Fourth Quarter Financial Results: * Total Revenue Increased 84 Percent to $275 Million * Product Sales Increased 96 Percent to $252 Million * REVLIMID(R) Net Product Sales Reached $124 Million * THALOMID(R) Net Product Sales Increased to $110 Million * Adjusted Earnings Per Share Increased 500 Percent to $0.18 Per Diluted Share 2006 Full-Year Financial Results: * Total Revenue Increased 67 Percent to $899 Million * Net Product Sales Increased 82 Percent to $812 Million * REVLIMID Net Produc...  01/30/07 Celgene Corporation Will Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference SUMMIT, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday, February 6, 2007 at 8:40 am ET will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chairman and Chief Executive Officer will provide an overview of the company. Celgene Corporation...  01/19/07 Celgene Corporation to Announce Fourth Quarter and Year-End 2006 Results on February 1, 2007 SUMMIT, N.J., Jan 19, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) senior management will host a conference call and live audio webcast on February 1, 2007 at 9:00 am ET to discuss the Company's fourth quarter and year-end 2006 financial and operational results. The webcast will be available in the investor relations section of the Company's website at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated ...  01/08/07 Celgene Corporation Reviews 2006 Achievements and Announces 2007 Financial Outlook - Company Reports Exceptional Operating Performance in 2006 Driven by Record Revenue And Profits - Total Revenue for 2006 Increased Approximately 60 Percent to $890 Million Range (Unaudited) - REVLIMID(R) Net Product Sales Reached a Range of $315 to $320 Million (Unaudited) - THALOMID(R) Net Product Sales Reached a Range of $425 to $430 Million (Unaudited) - Adjusted Diluted Earnings Per Share Expected to Nearly...  01/08/07 Celgene Corporation Elects James J. Loughlin to Board of Directors SUMMIT, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced the election of James J. Loughlin to the Company's Board of Directors. Mr. Loughlin is an experienced corporate director with a distinguished 40-year career with one of the world's leading professional accounting and business consulting firms where he reached the highest levels of corporate management and governance from entry level in 1964 to National Director of the Pharmaceuticals Practice, i...  01/02/07 Celgene Corporation Elects Sol J. Barer, Ph.D. to Chairman of the Board SUMMIT, N.J., Jan 02, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that its Board of Directors elected Sol J. Barer, Ph.D., Chief Executive Officer, to the additional position of Chairman of the Board, effective immediately. Dr. Barer has been our Chief Executive Officer since May 1, 2006, one of our Directors since March 1994, and is a member of the Executive Committee of our Board of Directors. Dr. Barer served as President from Octo...  12/27/06 Celgene Will Present at JP Morgan 25th Annual Healthcare Conference SUMMIT, N.J., Dec 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the JP Morgan Healthcare Conference on Monday, January 8, 2007 at 4:30 pm PST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Sol J. Barer, Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is ...  12/26/06 Celgene Notified of ANDA Filing for Thalidomide SUMMIT, N.J., Dec. 26 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the Company has been notified of an Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration (FDA), with a Paragraph IV certification, by Barr Pharmaceuticals, Inc. This applicant is seeking authorization to market a generic version of thalidomide 100 mg and 50 mg tablets in the United States for the acute treatment of cutaneous manifestations of moderate to...  12/13/06 Celgene Notified of ANDA Filing for Thalidomide SUMMIT, N.J., Dec. 13 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the Company has been notified of an Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration (FDA), with a Paragraph IV certification, by Barr Pharmaceuticals, Inc. This applicant is seeking authorization to market a generic version of thalidomide 200 mg tablets in the United States for the acute treatment of cutaneous manifestations of moderate to severe er...  12/11/06 Celgene Acquires API Manufacturing Facility in Europe SUMMIT, N.J., Dec 11, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that it has acquired active pharmaceutical ingredient (API) manufacturing facility from Siegfried Ltd. (SWX: SFZN), a manufacturer of high-quality pharmaceutical products located in Zofingen, Switzerland. Celgene is purchasing the assets for approximately a total of $46.5 million in cash, with an initial payment of $12.5 million. The manufacturing facility has the capab...  12/08/06 49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting 131 Abstracts Investigating Celgene Products in Single and Combination Therapies in a Broad Range of Hematological Cancers SUMMIT, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of REVLIMID (lenalidomide) at the American Society of Hematology 48TH Annual Meeting, considered the premier educational and sci...  12/07/06 131 Abstracts Evaluating Celgene Products to Be Presented at the 48th American Society of Hematology Meeting Seventy-Three Abstracts Investigating THALOMID(R) in Single and Combination Therapies in a Broad Range of Hematological Cancers SUMMIT, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of THALOMID (thalidomide) at the American Society of Hematology 48th Annual Meeting, one of the largest oncology meetings in t...  12/07/06 Celgene Appoints Thomas O. Daniel, M.D. as President of Global Research SUMMIT, N.J., Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that Thomas O. Daniel, M.D. has joined the Company as President of Celgene Research. Dr. Daniel brings to Celgene more than two decades of medical and pharmaceutical research experience, having most recently served as the Chief Scientific Officer at Ambryx, Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Prior to that, Dr....  12/07/06 Celgene Names David W. Gryska Chief Financial Officer SUMMIT, N.J., Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that David W. Gryska has joined the company as Chief Financial Officer. Mr. Gryska brings with him extensive business experience as having served as a Chief Financial Officer of public companies for more than ten years, most recently at SCIOS Inc., a biopharmaceutical company that was acquired by Johnson & Johnson. Earlier in his career, Mr. Gryska spent eleven years at...  11/03/06 Celgene Announces Pricing of Common Stock Offering SUMMIT, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG), announced the pricing of its public offering of 20,000,000 shares of its common stock at a public offering price of $51.60 per share. The gross proceeds of the offering will be $1.032 billion. This offering of the shares of Celgene common stock may be made only by means of a prospectus. A copy of the prospectus relating to the securities can be obtained from: J.P. Morgan Securities Inc., 277 Park Ave...  11/01/06 Celgene Intends to Issue Up to Approximately 20 Million Shares of Common Stock in S&P 500 Inclusion Transaction SUMMIT, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG), announced that as a result of the decision by Standard and Poor's Corporation to include Celgene Corporation in the S&P 500 Index, the Company intends to issue up to approximately 20 million shares of its common stock. The purpose of the offering is to partially meet the anticipated demand of index funds to purchase Celgene common stock when the Company is added to the S&P 500 Index, curre...  10/26/06 Celgene Corporation Reports Record Third Quarter Revenue and Operating Profits Product Sales Drive Record Third Quarter Revenue and Profits: * Record Net Product Sales of $223.1 Million - REVLIMID Achieved $101.3 Million in Net Product Sales - THALOMID Net Product Sales Totaled $108.4 Million * Record Adjusted Net Income of $59.4 Million with Adjusted Diluted Earnings Per Share of $0.15 Financial Highlights of Third Quarter Performance Year-Over-Year: * Total Revenue Increased 89.1% to a Record $244.8 Million ...  10/19/06 Celgene Corporation to Announce Third Quarter Results on October 26, 2006 SUMMIT, N.J., Oct. 19 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) senior management will host a conference call and live audio webcast on October 26, 2006 at 9:00 a.m. ET to discuss the Company's third quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged p...  10/04/06 Clinical Data From REVLIMID(R) Study in Myelodysplastic Syndromes Reported in New England Journal of Medicine SUMMIT, N.J., Oct. 4 /PRNewswire-FirstCall/ -- The New England Journal of Medicine today published final results of a Celgene Corporation (Nasdaq: CELG) sponsored Phase II trial evaluating REVLIMID(R) (lenalidomide) as an oral therapy for patients with myelodysplastic syndromes (MDS) with transfusion- dependent anemia and deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. MDS is a malignant disorder of blood cell production that affects approximat...  10/02/06 Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies Preliminary Phase II Data Evaluate REVLIMID Oral Therapy in Patients with Aggressive Non-Hodgkin's Lymphoma PALERMO, Italy, Oct. 2 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced clinical data from a multi-center, single arm open label Phase II clinical study evaluating and investigating single agent REVLIMID (lenalidomide) in patients with relapsed and refractory aggressive non-Hodgkins lymphoma (NHL) were reported at the 3rd Internationa...  09/20/06 Celgene Will Present at UBS Global Life Sciences Conference SUMMIT, N.J., Sept. 20 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the UBS Global Life Sciences Conference on Wednesday, September 27, 2006 at 9:30 a.m. EDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, Chief Executive Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is a...  09/18/06 Celgene Will Present at Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference SUMMIT, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference on Wednesday, September 20, 2006 at 4:00 pm BST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corpora...  09/01/06 Celgene Will Present at NewsMakers in the Biotech Industry Conference SUMMIT, N.J., Sept. 1 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the NewsMakers in the Biotech Industry Conference on Thursday, September 7, 2006 at 11:30 am EDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Celgene senior management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an inte...  08/04/06 Celgene Will Present at Bank of America Specialty Pharmaceutical Conference SUMMIT, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Bank of America Specialty Pharmaceuticals Conference on Thursday, August 10, 2006 at 3:45 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com . Celgene senior management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integra...  07/27/06 Celgene Corporation Reports Record Revenue and Operating Profits REVLIMID(R) and THALOMID(R) Regulatory Approvals Highlight Second Quarter Performance Product Sales Drive Record Second Quarter Revenue and Profits: - Total Net Product Sales Reached a Record $176.4 Million - REVLIMID Achieved $63.0 Million in Net Product Sales - THALOMID Net Product Sales Attained $107.2 Million - Adjusted Second Quarter Earnings Per Diluted Share Increased to $0.11 Financial Highlights of Second Quarter Performance: ...  07/19/06 Celgene Corporation to Announce Second Quarter Results on July 27, 2006 SUMMIT, N.J., July 19 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) senior management will host a conference call and live audio webcast on July 27, 2006 at 9:00 am ET to discuss the Company's second quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at http://www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engage...  06/29/06 REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma Third FDA Approval for Celgene Corporation in Six Months SUMMIT, N.J., June 29 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID (lenalidomide), for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. REVLIMID is also approve...  06/20/06 Celgene Will Present at NASDAQ Investor Program SUMMIT, N.J., June 20 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the NASDAQ 17th Investor Program on Wednesday, June 21, 2006 at 8:30 am BST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com . Celgene senior management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharma...  06/05/06 REVLIMID(R) (Lenalidomide) Survival Data Evaluated In Previously Treated Multiple Myeloma Updated Clinical Data Evaluating Lenalidomide in Multiple Myeloma Reported at 42nd American Society of Clinical Oncology Oral Session ATLANTA, June 5 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced updated clinical data from two multi-centered, randomized, double-blind, placebo-controlled Phase III pivotal studies evaluating lenalidomide plus dexamethasone in previously treated multiple myeloma patients were presented at the 42nd American Society of Cl...  06/05/06 REVLIMID(R) (Lenalidomide) Evaluated as Combination Oral Treatment Regimen in Elderly Newly Diagnosed Multiple Myeloma Updated Clinical Data Evaluating Lenalidomide in Newly Diagnosed Multiple Myeloma reported at 42nd American Society of Clinical Oncology Oral Session ATLANTA, June 5 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that clinical data from a study with combination therapy lenalidomide, melphalan and prednisone (R-MP) in elderly newly diagnosed multiple myeloma patients were reported at an oral presentation during the 42nd American Society of Clinical Oncology (A...  06/05/06 THALOMID(R) (Thalidomide) Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma Updated Clinical Data Evaluating THALOMID in Multiple Myeloma Reported at the 42nd American Society of Clinical Oncology Oral Session ATLANTA, June 5, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that updated clinical data from an ongoing multi- centered, randomized, placebo-controlled phase III study (MM-003) of oral combination therapy thalidomide plus dexamethasone versus dexamethasone alone as induction therapy for previously unt...  06/05/06 Thalidomide Survival Data Evaluated in Newly Diagnosed Multiple Myeloma Clinical Data Evaluating THALOMID in Newly Diagnosed Multiple Myeloma Presented at the 42nd American Society of Clinical Oncology Plenary Session ATLANTA, June 5 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced results from an ongoing randomized trial evaluating the treatment of newly diagnosed, multiple myeloma patients with oral combination therapy thalidomide, melphalan and prednisone. The clinical data evaluating thalidomide in newly diagnosed multiple m...  05/25/06 Thalomid(R) sNDA Granted FDA Approval For Treatment of Newly Diagnosed Multiple Myeloma SUMMIT, N.J., May 25 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to its Supplemental New Drug Application (sNDA) for THALOMID (thalidomide) in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma. The effectiveness of THALOMID is based upon response rates. There are no controlled trials demonstrating a clinical benefit, such as an improvement in ...  05/16/06 Celgene Cellular Therapeutics Strengthens Intellectual Property Estate in the Field of Placental-Derived Stem Cells Patent Issued to Protect Proprietary Methodologies of Celgene Cellular Therapeutics for Recovering Placental-Derived Stem CellsSUMMIT, N.J., May 16, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Cellular Therapeutics (CCT), a wholly owned subsidiary of Celgene Corporation (Nasdaq: CELG) announced that its intellectual property estate was strengthened by the issuance of United States Patent No. 7,045,148 by the United States Patent & Trademark Office (USPTO). This patent is t...  05/11/06 Celgene Will Present at Bank of America Healthcare Conference SUMMIT, N.J., May 11 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Bank of America Healthcare Conference on Tuesday, May 16, 2006 at 8:00 am PDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jerse...  04/28/06 Celgene Will Present at Morgan Stanley Global Healthcare Unplugged Conference SUMMIT, N.J., April 28 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, May 3, 2006 at 2:15 pm EDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com . Robert J. Hugin, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered ...  04/28/06 Celgene Will Present at Deutsche Bank Securities Annual Healthcare Conference SUMMIT, N.J., April 28, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Deutsche Bank Securities 31st Annual Healthcare Conference on Tuesday, May 2, 2006 at 11:15 am EDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, Chief Executive Officer will provide an overview of the company. Celgene Corporation, head...  04/27/06 Celgene Corporation Reports Record Revenue and Operating Profits Product Sales Drive Record First Quarter Revenue and Profits: Strong REVLIMID(R) Launch Achieved $32.4 Million in Net Product Sales Record THALOMID(R) Net Product Sales Increased 21.3% to $107.2 Million Versus First Quarter 2005 Market Share Gains Drive Ritalin(R)/Focalin(TM) Revenue Increase of 84.4% to $19.4 Million Versus Prior Year Quarter Financial Highlights of First Quarter Performance: Total Revenue Increased 61.8% to a Record $181...  04/26/06 Celgene Will Present at Baird Growth Stock Conference SUMMIT, N.J. April 26 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Baird 2006 Growth Stock Conference on Wednesday, May 10, 2006 at 9:40 am CDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com . Perry Karsen, Senior Vice President, Business Development will provide an overview of the company. Celgene Corporation, headquartered in Summit, New J...  04/20/06 Celgene Corporation Elects Rodman L. Drake To Board of Directors SUMMIT, N.J., April 20 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced Thursday, April 20th, the election of Rodman L. Drake to the Company's Board of Directors. Mr. Drake is an experienced corporate director and former CEO with more than 30 years of diverse consulting and executive management experience. He will serve as a member of the Nominating and Audit Committees of the Celgene Board of Directors. Mr. Drake has spent most of his career in executive level p...  04/19/06 Celgene Corporation to Announce First Quarter Results on April 27, 2006 SUMMIT, N.J., April 19 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) senior management will host a conference call and live audio webcast on April 27, 2006 at 9:00 AM ET to discuss the Company's first quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at http://www.celgene.com. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceu...  04/18/06 LifebankUSA(TM) Announces New Service to Bank Placental-Derived Stem Cells New Technology Available to Expecting Families Builds on Celgene Cellular Therapeutics Deep Experience and Patented Procedures CEDAR KNOLLS, N.J., April 18 /PRNewswire-FirstCall/ -- LifebankUSA, a subsidiary of Celgene Cellular Therapeutics (CCT), today announced plans for a new service to bank stem cells derived from the placenta. Placental-derived stem cells (PDSCs), which have different characteristics from those isolated...  04/07/06 REVLIMID(R) Marketing Authorization Application Accepted by EMEA for Review REVLIMID is Being Evaluated by the EMEA as Oral Therapy for Treatment for Patients with Relapsed or Refractory Multiple Myeloma SUMMIT, N.J., April 7 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG), announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for LENALIDOMIDE - CELGENE EUROPE (lenalidomide), submitted in February 2006. The application is based upon the safety and efficacy results of...  03/06/06 Clinical Data Evaluating CC-10004 as New Oral Therapy in Severe Psoriasis Data Presented at the American Academy of Dermatology Meeting SAN FRANCISCO, March 6 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that phase II data, evaluating CC-10004 - a novel compound with anti-inflammatory activities - as a potential oral-therapy for patients with severe plaque-type psoriasis, were reported at the 64th Annual American Academy of Dermatology meeting in San Francisco, Calif on Sunday, March 5, 2006. Psoriasis is a lifelong ski...  03/03/06 FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of Relapsed or Refractory Multiple Myeloma June 30, 2006 PDUFA Date Established Expanded Access Program to Remain Open Through FDA Action on REVLIMID sNDA SUMMIT, N.J., March 3 /PRNewswire-FirstCall/ - Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its Supplemental New Drug Application (sNDA) for REVLIMID (lenalidomide) for the treatment of relapsed or refractory multiple myeloma. The Prescription Drug User F...  02/23/06 Celgene Will Present at Lehman Brothers Global Healthcare Conference SUMMIT, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Lehman Brothers Global Healthcare Conference on Wednesday, March 8, 2006 at 5:15 pm EST will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. Robert J. Hugin, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquartered in Su...  02/22/06 Celgene Will Present at JMP Securities Research Conference SUMMIT, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the JMP Securities Research Conference on Tuesday, March 7, 2006 at 7:30 am PST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Celgene senior management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pha...  02/21/06 Celgene Will Present at Bear Stearns London Healthcare Conference Feb 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Bear Stearns London Healthcare Conference on Wednesday, March 1, 2006 at 9:20 am GMT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com . Celgene senior management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an int...  02/17/06 Celgene Shareholders Approve Increase in Authorized Shares Friday, February 17, 2006 Record Date for Two-for-One Stock Split Celgene Share Price Expected to be Reported on Split-Adjusted Basis on Monday, February 27, 2006 SUMMIT, N.J., Feb. 17 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that its shareholders approved an increase in the number of authorized shares of stock from 280,000,000 to 580,000,000 at a Special Meeting of the Stockholders on February 16, 2006. The record...  02/02/06 Celgene Will Present at Citigroup Healthcare Conference SUMMIT, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the 2006 Citigroup Healthcare Conference on Monday, February 27, 2006 at 1:20 pm EST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey...  02/01/06 Celgene Will Present at BIO CEO and Investor Conference SUMMIT, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the BIO CEO and Investor Conference on Tuesday, February 14, 2006 at 2:00 pm EST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is...  01/31/06 Celgene Will Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Conference SUMMIT, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the 17th Annual Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device Conference on Tuesday, February 7, 2006 at 11:00 am EST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice President and Chief Financial Officer will provide an overview of...  01/26/06 Celgene Corporation Reports Record Operating Performance for 2005 42% Increase in Total Revenue For 2005 Versus Prior Year 35% Annual Increase in Total Product Sales For 2005 100% Increase in Adjusted Operating Income Year-Over-Year Fourth Quarter Highlights: REVLIMID(R) NDA Granted FDA Approval for MDS Deletion 5q REVLIMID sNDA Submitted to FDA for Relapsed or Refractory Multiple Myeloma REVLIMID MAA Filing Under Review at EMEA for MDS Deletion 5q REVLIMID MAA Submitted to Switz...  01/09/06 Celgene Corporation Reviews Recent Highlights and Outlines 2006 Milestones - Recent Highlights * REVLIMID(R) NDA Granted FDA Approval for MDS Deletion 5q * REVLIMID sNDA Submitted to FDA for Relapsed or Refractory Multiple Myeloma Indication * REVLIMID MAA Filing Under Review at EMEA for MDS/Deletion 5q Indication * REVLIMID MAA Submitted to Switzerland for MDS/Deletion 5q Indication * More Than 100 Abstracts at ASH 2005; 23 Oral Presentations Including Survival Data for REVLIMID ...  01/09/06 THALOMID(R) Pivotal Phase III Multiple Myeloma Trial Reaches Pre-Specified Interim Endpoint Independent Data Monitoring Committee review determines that the Phase III pivotal trial (MM-003) meets the pre-established efficacy-stopping rule of p SUMMIT, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that an external Independent Data Monitoring Committee analysis of the multi-centered, randomized, placebo-controlled phase III study of combination thalidomide plus dexamethasone versus dexamethasone alone as induction therapy for ...  01/06/06 Celgene Corporation to Announce Fourth Quarter and Year-End 2005 Results On January 26, 2006 SUMMIT, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) senior management will host a conference call and live audio webcast on January 26, 2006 at 9:00 AM ET to discuss the Company's fourth quarter and year-end 2005 financial and operational results. The webcast will be available in the investor relations section of the Company's website at http://www.celgene.com. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrat...  01/04/06 Celgene Will Present at JP Morgan 24th Annual Healthcare Conference SUMMIT, N.J., Jan. 4 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the JP Morgan Healthcare Conference on Monday, January 9, 2006 at 9:30 am PST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, President and Chief Operating Officer will provide an overview of the company. About Celgene Celgene Corporation, headquartered in Summi...  12/27/05 Celgene Corporation Announces Two-For-One Stock Split SUMMIT, N.J., Dec 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that its Board of Directors has approved a two-for-one stock split, payable in the form of a 100 percent stock dividend. The stock split is subject to stockholder's approval to increase the number of authorized shares of common stock from 280,000,000 to 580,000,000, an action that will be voted on at a Special Meeting of the Stockholders on February 16, 2006. If approve...  12/27/05 Celgene Corporation Announces Senior Management Transition Plan Changes to be Effective May 1, 2006 SUMMIT, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) Celgene Corporation announced today that its Chairman and Chief Executive Officer John W. Jackson will retire as Chief Executive Officer on May 1, 2006. Mr. Jackson will continue as Chairman of the Board of Directors and stand for re-election at the Company's annual meeting on June 15, 2006. On May 1st, Sol J. Barer will assume responsibility as th...  12/27/05 FDA Grants REVLIMID(R) NDA Approval SUMMIT, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) granted approval of REVLIMID (lenalidomide) which is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID will be available through a REVLIMID...  12/13/05 REVLIMID(R) Clinical Results as Oral Treatment Regimen in Newly Diagnosed Multiple Myeloma Presented at the 47th American Society of Hematology Meeting ATLANTA, Dec. 13 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that new data evaluating clinical results on the treatment of newly diagnosed multiple myeloma patients with REVLIMID (lenalidomide) and dexamethasone as an oral combination therapy were reported at the 47th American Society of Hematology (ASH) Meeting in Atlanta, GA. Multiple myeloma (MM) is the second most common cancer of the blood, representing approximately one percent of all cancers and two pe...  12/13/05 REVLIMID(R) Clinical Results as Oral Treatment Regimen in Myelofibrosis Presented at the 47th American Society of Hematology Meeting ATLANTA, Dec. 13 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that clinical data from a REVLIMID (lenalidomide) study in myelofibrosis (MF) were reported at an oral presentation during the 47th American Society of Hematology (ASH) Meeting in Atlanta, GA. The Phase II study evaluated previously treated patients with myelofibrosis, a rare blood disorder that can be fatal if untreated. To date, there are no drugs approved for the treatment of this disease. A...  12/12/05 REVLIMID(R) Clinical Results as Oral Treatment Regimen in Chronic Lymphocytic Leukemia Presented at the 47th American Society of Hematology Meeting ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that clinical data from a REVLIMID study in Chronic Lymphocytic Leukemia (CLL) were reported at an oral presentation during the 47th American Society of Hematology (ASH) Meeting in Atlanta, GA on Monday, December 12, 2005. The study reported that sixteen out of nineteen evaluable patients achieved stable disease or better after treatment with REVLIMID, and experienced a median decrease ...  12/11/05 Revlimid(R) Improves Overall Survival and Delays Time to Disease Progression in Previously Treated Multiple Myeloma Patients Updated Clinical Data Evaluating REVLIMID in Multiple Myeloma Reported at the 47th American Society of Hematology Meeting Plenary SessionATLANTA, Dec 11, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced updated clinical data from two Phase III pivotal studies evaluating REVLIMID (lenalidomide) plus dexamethasone in previously treated multiple myeloma patients. The updated clinical data from the pivotal International Phase III trial (MM-010),...  12/08/05 107 Abstracts on Clinical Data Evaluating REVLIMID(R) and Thalidomide To Be Presented at The 47th American Society of Hematology Meeting SUMMIT, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of thalidomide, and REVLIMID in multiple indications at The 47th American Society of Hematology Meeting, one of the largest oncology meetings in the world, in Atlanta, GA from December 10-13, 2005. The presentations will include 30 abstracts clinically evaluating ...  11/15/05 Celgene Receives Approvable Letter From FDA for THALOMID(R) in Treatment of Newly Diagnosed Multiple Myeloma SUMMIT, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) today announced the U.S. Food and Drug Administration (FDA) issued an approvable letter in response to the Company's sNDA for multiple myeloma (MM). The FDA has requested revised product labeling with the specific indication of newly diagnosed multiple myeloma and updated safety information, as well as some additional patient information to finalize its review. The THALOMID sNDA is based on results f...  11/03/05 Clinical Data on Thalidomide Reported in Recurrent Epithelial Ovarian Cancer Oral Presentation at the Chemotherapy Foundation Symposium Reported 50% of Patients Achieved Overall Response in Median Progression Free Survival SUMMIT, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that preliminary clinical data was reported at the XXIII Chemotherapy Foundation Symposium in New York City, New York on Thursday, November 3, 2005 comparing the efficacy and safety of the combination of thalidomide and topotecan vs. topote...  11/03/05 Celgene Corporation Reports Strong Operating, Regulatory and Clinical Results with Record Product Sales Third Quarter Highlights: Total Product Sales for the Third Quarter Reached a Record $113.9 Million, 36% Increase Year-Over-Year Commercial Team Finalized Preparations for REVLIMID(R) Launch As First Oral Targeted Therapy For Low To Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality FDA Oncologic Drugs Advisory Committee Recommended REVLIMID for Full Approval, by a 10-5 vote, As Oral Targeted Therapy For Low To Intermediat...  10/28/05 Celgene Corporation to Announce Third Quarter Results on November 3, 2005 SUMMIT, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) senior management team plans to report its third quarter financial and operational results on Thursday, November 3, 2005 at 8:00 am EST, before the open of the financial markets. The webcast will be available in the investor relations section of the Company's website at http://www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company...  10/26/05 REVLIMID(R) Marketing Authorization Application Accepted by EMEA for Review REVLIMID Being Evaluated by the EMEA as Oral Targeted Therapy for Treatment of Patients with Myelodysplastic Syndromes (MDS) with Deletion 5q Chromosomal Abnormality SUMMIT, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (MAA) for REVLIMID (lenalidomide), submitted in August 2005. The application is ...  10/03/05 REVLIMID(R) PDUFA Date Extended Three Months By FDA Extension to Allow for Completion of Review of REVLIMID Risk-Management Program Celgene Prepared for REVLIMID Launch As First Oral Targeted Therapy For Low To Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality Celgene Expects November Filing of REVLIMID application for Multiple Myeloma SUMMIT, N.J., Oct. 3 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that they received notification late Friday ...  09/14/05 FDA Oncologic Drugs Advisory Committee Recommends REVLIMID(R) for Full Approval By a 10-5 Vote, ODAC Recommends REVLIMID as Oral Targeted Therapy for Low to Intermediate-1-Risk MDS Patients With Deletion 5q Chromosomal Abnormality WASHINGTON, Sept 14, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) recommended full approval of REVLIMID (lenalidomide) for the treatment of patients with transfusion- dependent anemia due to ...  09/13/05 FDA and Celgene Revlimid(R) Briefing Documents for Advisory Committee Meeting Available Online WASHINGTON, Sept 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the ODAC meeting scheduled to review the REVLIMID(R) (lenalidomide) New Drug Application (NDA) seeking approval for REVLIMID for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk ...  09/09/05 Celgene Will Present at Bear Stearns Healthcare Conference SUMMIT, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Bear Stearns Healthcare Conference on Monday, September 12, 2005 at 9:30 am EDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. John W. Jackson, Chairman and CEO will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated ...  09/08/05 Celgene Will Present at Thomas Weisel Healthcare Tailwinds Conference SUMMIT, N.J., Sept 08, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Thomas Weisel Healthcare Tailwinds on Friday, September 9, 2005 at 11:00 am EDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corpor...  09/07/05 Celgene Will Present at NewsMakers in the Biotech Industry Conference SUMMIT, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at NewsMakers in the Biotech Industry Conference on Friday, September 9, 2005 at 11:00 am EDT will be webcast live and will be available in the investor relations section of the Company's website at www.celgene.com. John W. Jackson, Chairman and CEO will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated ...  07/28/05 Celgene Corporation Reports Record Operating Performance and Key Clinical and Regulatory Progress Record Second Quarter Revenue and Profits: Total Revenue Increased 66 Percent Year-Over-Year Net Operating Profits Increased More Than 300 Percent Year-Over-Year Earnings Per Diluted Share More Than Doubled Year-Over-Year Company Affirms 2005 Financial Targets REVLIMID(R), THALOMID(R) and FOCALIN XR(TM) Clinical and Regulatory Programs Advanced: FDA Granted Priority Review for REVLIMID NDA for Treatment of Low and Intermediate R...  07/20/05 Celgene Corporation to Announce Second Quarter Results on July 28, 2005 SUMMIT, N.J., July 20 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that it plans to report its second quarter results on Thursday, July 28, 2005 before the open of the financial markets. Following the announcement senior management will host a conference call and live audio webcast at 9:00 am EDT to discuss the Company's second quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at ht...  07/18/05 Celgene Corporation Second Quarter 2005 Earnings Conference Call SUMMIT, N.J.--(BUSINESS WIRE)--July 18, 2005--Celgene Corporation (NASDAQ:CELG) will announce second quarter operational and financial results on Thursday, July 28, 2005. Celgene's management team will host a conference call and live audio webcast to discuss the financial and operational results. The webcast will be available in the investor relations sections of the Company's website at www.celgene.com and will be archived for two weeks. The webcast is also being distributed...  06/24/05 Celgene Added to the Nasdaq-100 Index Effective Prior to Market Open on Tuesday, July 5, 2005 SUMMIT, N.J., June 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG), a leading global biopharmaceutical company, announced that it will be added to the Nasdaq-100 Index(R), effective prior to market open on Tuesday, July 5, 2005. Shares of CELG will also be included in the Nasdaq-100 Index Tracking Stock (Nasdaq: QQQQ). "Our addition to the Nasdaq-100 Index is a result of the outstanding perfor...  06/21/05 FDA Grants Priority Review for REVLIMID(R) NDA for Treatment of Low- and Intermediate- Risk MDS With Deletion 5q Chromosomal Abnormality SUMMIT, N.J., June 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its New Drug Application (NDA) for REVLIMID with a Prescription Drug User Fee Act (PDUFA) date by October 7, 2005. The Company is seeking approval to market REVLIMID as a targeted treatment for transfusion-dependent patients with low- and intermediate-risk myelodysplastic syndromes (MDS) w...  06/16/05 Celgene Will Present at FBR European Investor Conference SUMMIT, N.J., June 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the FBR European Investor Conference on Wednesday, June 29, 2005 at 10:10 am BST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquart...  06/15/05 Celgene Will Present At Goldman Sachs Global Healthcare Conference SUMMIT, N.J., June 15 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the 26th Annual Goldman Sachs Global Healthcare Conference on Thursday, June 16, 2005 at 11:00 am PDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, he...  06/07/05 REVLIMID® (lenalidomide) New Drug Application Accepted for Review by FDA New Drug Application Based on Phase II Trial (MDS-003) in Myelodysplastic Syndromes Patients with Deletion 5q Chromosomal Abnormality SUMMIT, NJ – (June 7, 2005) –Celgene Corporation (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) has formally accepted for review the Company's New Drug Application (NDA) for REVLIMID. The REVLIMID NDA is seeking approval as a targeted treatment for transfusion-dependent myelodysplastic syndromes (MDS) patients with deletion 5q ch...  06/06/05 REVLIMID(R) (lenalidomide) Study in Low and Intermediate-1 Risk Myelodysplastic Syndromes Presented at the 10th Congress of the European Hematology Association 51% of Eligible Low and Intermediate-1 Risk Transfusion Dependent Myelodysplastic Syndromes (MDS) Patients Without Deletion 5q Chromosomal Abnormality Achieve Hematologic Improvement, with 33% Achieving Transfusion Independence Transfusion Independence Maintained for a Median of 41 Weeks in Responders Median Hemoglobin Increased 3.2 g/dl From a Baseline of 8.0 g/dl in Responders 45% of Evaluable Patients Experience Cytogenetic ...  05/27/05 FDA Grants Approval to Market FOCALIN XR(TM) for the Treatment of ADHD in Adults, Adolescents and Children SUMMIT, N.J., May 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced that Novartis Pharma AG, its partner in the development and commercialization of FOCALIN XR, was granted U.S. Food and Drug Administration (FDA) approval for FOCALIN XR (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults, adolescents and children. The approval of FOCALIN XR for the treatment of ADHD was ba...  05/20/05 Celgene Will Present at Needham & Company Fourth Annual Biotechnology Conference SUMMIT, N.J., May 20 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Needham and Company Biotechnology Conference on Wednesday, May 25, 2005 at 10:00 am EDT, will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com . Perry Karsen, Senior VP Business Development, will provide an overview of the Company. Celgene Corporation, headquartered in Summit, New Jers...  05/19/05 Celgene Will Present at UBS 2005 Global Pharmaceuticals Conference SUMMIT, N.J., May 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the UBS Global Pharmaceuticals Conference on Tuesday, May 24, 2005 at 10:00 am EDT, will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. John W. Jackson, Chairman and CEO, will provide an overview of the Company. Celgene Corporation, headquartered in Summit, New Jersey, is...  05/15/05 REVLIMID(R) (lenalidomide) Significantly Delays Time to Disease Progression in Previously Treated Multiple Myeloma Patients Presented at 2005 ASCO - Overwhelmingly Positive Statistically Significant Difference in The Primary Endpoint of Time-To-Progression (TTP) Demonstrated in Two Pivotal Phase III Special Protocol Assessment Trials (SPA) - Updated Clinical Data Presented at ASCO Scientific Symposium - The median time-to-disease progression in the North American Phase III Trial (MM-009) with REVLIMID plus dexamethasone was 60.1 weeks, compared with the median time-to-disease progr...  05/15/05 REVLIMID(R) Study in Myelodysplastic Syndromes With Deletion 5Q Chromosomal Abnormality Presented at ASCO Plenary Session 66% of Transfusion-Dependent Myelodysplastic Syndromes (MDS) Patients Achieved Transfusion Independence and a Median Hemoglobin Increase 5.3g/dl, on an Intent-To-Treat Basis 73% of Responders have Remained Transfusion Independent with a Median Duration of 58 Weeks of Follow-Up; Median Duration of Transfusion Independence Not Yet Reached Cytogenetic Response Achieved in 70% of Patients Evaluated; Complete Cytogenetic Response in 63...  05/15/05 REVLIMID(R)(Lenalidomide) Study in Chronic Lymphocytic Leukemia Presented at 2005 ASCO ORLANDO, Fla., May 15 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that clinical data from a REVLIMID study in Chronic Lymphocytic Leukemia (CLL) were presented at the 2005 American Society Clinical Oncology (ASCO) Meeting in Orlando, Florida, at a poster session, on Saturday, May 14. Clinical results were presented on REVLIMID as a potential new approach for treating patients with relapsed or refractory CLL. Chronic Lymphocytic Leukemia is a hematological c...  05/06/05 Celgene Will Present at Baird Growth Stock Conference SUMMIT, N.J., May 6 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Baird Growth Stock Conference on Wednesday, May 11, 2005 at 11:25 am CDT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Alan Lewis, President of Celgene Signal Research will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integ...  05/02/05 Celgene Will Present at Bear Stearns Healthcare Conference in London SUMMIT, N.J., May 2, 2005 /PRNewswire-FirstCall via COMTEX/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Bear Stearns London Healthcare Conference on Tuesday, May 10, 2005 at 11:00 am UKT will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Sum...  04/28/05 Celgene Corporation First Quarter Results Deliver Record Operating Performance and Key Clinical and Regulatory Progress Product Sales Drive Record First Quarter Revenue and Profits: Total Revenue Increased Approximately 36 Percent Year-Over-Year Adjusted Earnings Per Diluted Share More Than Doubled Versus Prior Year Company Affirms 2005 Financial Targets REVLIMID(R)(lenalidomide) Clinical and Regulatory Programs Advanced: REVLIMID Pivotal Phase III Special Protocol Assessment (SPA) Multiple Myeloma (MM) Trials Reported Overwhelming Statistically S...  04/21/05 Celgene Corporation to Announce First Quarter Results on April 28, 2005 SUMMIT, N.J., April 21 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) senior management will host a conference call and live audio webcast on April 28, 2005 at 9:00 am EDT to discuss the Company's first quarter financial and operational results. The webcast will be available in the investor relations section of the Company's website at http://www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company en...  04/19/05 Celgene Will Present at Rodman & Renshaw Global Healthcare Conference in Paris SUMMIT, N.J., April 19 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Rodman & Renshaw Global Healthcare Conference on Thursday, May 5, 2005 at 12:40 pm CEST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, Ne...  04/13/05 International Stem Cell Meeting Reports Pluripotent Stem Cells Isolated From Placenta Ethically Non-Controversial Stem Cells Can Be Obtained from Placenta SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that human placenta-derived stem cells that are "pluripotent", or have the ability to become different types of tissue, can be isolated with a proprietary perfusion technology from placentas so they are available for potential treatment applications, according to an oral presentation yesterday at the International Conference...  04/11/05 Revlimid(R) (Lenalidomide) Clinical Data From Interim Analysis of Pivotal Phase III Special Protocol Assessment Trials in Previously Treated Myeloma Presented at the 10th International Multiple Myeloma Workshop Overwhelming Statistically Significant Difference (p is less-than 0.00001) In Time-To-Progression (TTP) Rates Validated by Two Pivotal Phase III Special Protocol Assessment Trials (SPA) After more than 15 months of follow-up, the primary endpoint of time-to-disease progression in the REVLIMID plus dexamethasone arm of U.S. Phase III Trial (MM-009) not reached, compared with median time-to-disease progression of 5 months for the dexam...  04/08/05 REVLIMID(R) New Drug Application Submitted to FDA for Review Clinical Data From Phase II Trial (MDS-003) in Patients With Myelodysplastic Syndromes With 5q Deletion Chromosomal Abnormality Submitted SUMMIT, N.J., April 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that it has completed the rolling submission of its New Drug Application (NDA) for REVLIMID (lenalidomide), an investigational drug, to the Division of Oncology Drug Products at the U.S. Food and Drug Administration (FDA) for review. The Company'...  03/24/05 Celgene Licenses Rights To EntreMed For Tubulin Inhibitor Program SUMMIT, N.J., March 24 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that it has signed a licensing agreement with EntreMed Corporation (ENMD) whereby EntreMed has been granted rights to the development and commercialization of Celgene's tubulin inhibitor compounds, a class of orally available, anti-proliferative compounds that have demonstrated, in preclinical models, activity against drug-resistant cancer cells, inhibition of inflammatory cytokines and anti-angio...  03/10/05 Celgene Will Present at Lehman Brothers Global Healthcare Conference SUMMIT, N.J., March 10 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Lehman Brothers Annual Global Healthcare Conference on Thursday, March 31, 2005 at 10:15 a.m. EST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, he...  03/09/05 Celgene Will Present at Smith Barney Citigroup Healthcare Conference SUMMIT, N.J., March 9 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Smith Barney Citigroup Healthcare Conference on Wednesday, March 30, 2005 at 10:20 am EST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. John W. Jackson, Chairman and CEO will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an i...  03/07/05 REVLIMID(R) Pivotal Phase III Multiple Myeloma Trials Both Exceed Pre-Specified Interim Efficacy Endpoint Independent Data Monitoring Committee review determines that both Phase III Special Protocol Assessment pivotal trials overwhelmingly exceeded the pre-established efficacy stopping rule of p Celgene will unblind the studies and allow all patients in these studies access to REVLIMID Discussions with FDA and international regulatory agencies are ongoing Plans being formulated to create expanded access programs for patients with previously treated myeloma SUMMIT, N....  02/11/05 Celgene Will Present at Leerink Swann Healthcare Conference SUMMIT, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Leerink Swann Healthcare Conference on Tuesday, March 1, 2005 at 10:00 am EST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Sol J. Barer, President and Chief Operating Officer will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, i...  02/10/05 Celgene Will Present at Wells Fargo Annual Healthcare Conference SUMMIT, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced today that its presentation at the Wells Fargo Annual Healthcare Conference on Tuesday, March 1, 2005 at 10:30 am EST will be webcast live and will be available in the investor relations section of the Company's website at http://www.celgene.com. Robert J. Hugin, Senior Vice President and Chief Financial Officer will provide an overview of the company. Celgene Corporation, headquartered in S...  02/09/05 Clinical Data From Initial REVLIMID(TM) Study in Myelodysplast